[go: up one dir, main page]

US20050287130A1 - Methods of modifying cell structure and remodeling tissue - Google Patents

Methods of modifying cell structure and remodeling tissue Download PDF

Info

Publication number
US20050287130A1
US20050287130A1 US11/205,562 US20556205A US2005287130A1 US 20050287130 A1 US20050287130 A1 US 20050287130A1 US 20556205 A US20556205 A US 20556205A US 2005287130 A1 US2005287130 A1 US 2005287130A1
Authority
US
United States
Prior art keywords
cells
leu
cell
biliverdin reductase
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/205,562
Inventor
Mahin Maines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Priority to US11/205,562 priority Critical patent/US20050287130A1/en
Publication of US20050287130A1 publication Critical patent/US20050287130A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR reassignment NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF ROCHESTER
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to methods of modifying cell structure and remodeling tissue which involve modulating the intracellular levels of biliverdin reductase or active fragments or variants thereof.
  • Biliverdin reductase (“BVR”) catalyzes reduction of the ⁇ -meso bridge of biliverdin, an open tetrapyrrole, to produce bilirubin (Singleton et al., J. Biol. Chem. 240: 47890-4789 (1965); Tenhunen et al., Biochemistry 9:298-303 (1970); Colleran et al., Biochem J. 119:16P-19P (1970); Kutty et al., J. Biol. Chem. 256:3956-3962 (1981); Buldain et al., Eur. J. Biochem. 156:179-184 (1986); Noguchi et al., Biochem J.
  • BVR is the only enzyme described to date with dual pH/dual adenine nucleotide cofactor requirements (Kutty et al., J. Biol. Chem. 256:3956-3962 (1981); Fakhrai et al., J. Biol. Chem. 267:4023-4029 (1992); Maines et al., Eur. J. Biochem. 235:372-381 (1996); Huang et al., J. Biol. Chem. 264:7844-7849 (1989)).
  • the reductase uses NADH in the acidic range (optimum range ⁇ pH 6.0-6.7), whereas NADPH is utilized in the basic range (optimum range ⁇ pH 8.5-8.7).
  • BVR which is a zinc metalloprotein (Maines et al., Eur. J. Biochem. 235:372-381 (1996)), possesses a HCX 10 CH or HCX 10 CC motif in the carboxy terminal third of the protein, which is similar to the zinc binding motif of protein kinase C (Hubbard et al., Science 254:1776-1779 (1991)) and may be the site of interaction of BVR with zinc.
  • BVR was previously thought to be simply a house-keeping enzyme found in most mammalian cells in excess of, or in disproportionate levels to, heme oxygenase isozymes (Ewing et al., J. Neurochem. 61:1015-1023 (1993)). Yet it has the above-noted noted unique and uncommon properties. Examination of the primary structure of human BVR, which recently became available (Maines et al., Eur. J. Biochem.
  • a valine residue is present in BVR just 2 positions downstream from the last glycine of this motif.
  • a valine residue is invariant at the corresponding position, as in BVR, in the family of kinases that phosphorylate G-protein coupled receptors (Garcia-Bustos et al., Biochim. Biophys. ACTA 1071:83-101 (1991)).
  • Database search results also identified additional similarities with PKGs, including a cluster of charged residues (KRNR) in the carboxy terminus of BVR. Such clusters are a characteristic of the nuclear localization signal (“NLS”) (Garcia-Bustos et al., Biochim. Biophys. ACTA 1071:83-101 (1991)).
  • BVR has previously been identified as exhibiting protective effects against oxidative stress and as sharing characteristics with known kinases (see U.S. patent application Ser. No. 09/606,129 to Maines, filed Jun. 28, 2000), it is unclear the extent to which BVR is implicated in cellular repair mechanisms.
  • the present invention is directed to overcoming the above-identified deficiencies in the art.
  • a first aspect of the present invention relates to a method of modifying cell structure which includes: increasing the intracellular concentration of biliverdin reductase, or a fragment or variant thereof, in a mammalian cell under conditions effective to modify the structure of the mammalian cell.
  • a second aspect of the present invention relates to a method of in vivo tissue remodeling in a mammal which includes: delivering biliverdin reductase, or fragments or variants thereof, to one or more cells present at a site of tissue remodeling in a mammal, wherein said delivering increases the intracellular concentration of biliverdin reductase, or fragments or variants thereof, under conditions effective to modify the structure of the one or more cells at the site of tissue remodeling, thereby remodeling the tissue containing the one or more cells.
  • a third aspect of the present invention relates to a method of repairing a damaged organ or organ system by performing the in vivo tissue modeling of the present invention, where the site of tissue remodeling is within the damaged organ or organ system.
  • FIGS. 1-6 show different images of HeLa cells transfected with human BVR DNA. Differences between untransfected cells (normal morphology) and transfected cells (immunostained) is readily apparent. The transfected cells show remarkable enlargement, altered cellular morphology including filopodia, and the appearance of spikes which are clearly observed.
  • the methods of modifying cell structure and remodeling tissue according to the present invention involve modulating the intracellular levels of biliverdin reductase (“BVR”) or active fragments thereof.
  • BVR biliverdin reductase
  • Modulating intracellular levels of BVR can be achieved using known recombinant techniques directed to cells or tissues to be affected, as described below, or by using known protein delivery techniques for delivering BVR into cells or tissues to be affected.
  • hBVR human biliverdin reductase
  • SEQ. ID. No. 1 has an amino acid sequence corresponding to SEQ. ID. No. 1 as follows: Met Asn Ala Glu Pro Glu Arg Lys Phe Gly Val Val Val Val Gly Val 1 5 10 15 Gly Arg Ala Gly Ser Val Arg Met Arg Asp Leu Arg Asn Pro His Pro 20 25 30 Ser Ser Ala Phe Leu Asn Leu Ile Gly Phe Val Ser Arg Arg Glu Leu 35 40 45 Gly Ser Ile Asp Gly Val Gln Gln Ile Ser Leu Glu Asp Ala Leu Ser 50 55 60 Ser Gln Glu Val Glu Val Ala Tyr Ile Cys Ser Glu Ser Ser Ser Ser His 65 70 75 80 Glu Asp Tyr Ile Arg Gln Phe Leu Asn Ala Gly Lys His Val Leu Val 85 90 95 Glu Tyr Pro Met Thr Leu Ser Leu Ala Ala Ala Gln Glu Leu Trp
  • hBVR Heterologous expression and isolation of hBVR is described in Maines et al., Eur. J. Biochem. 235(1-2):372-381 (1996); Maines et al., Arch. Biochem. Biophys. 300(1):320-326 (1993), each of which is hereby incorporated by reference in its entirety.
  • the DNA molecule encoding this form of hBVR has a nucleotide sequence corresponding to SEQ. ID. No.
  • hBVR has an amino acid sequence according to SEQ. ID. No. 3 as follows: Met Asn Thr Glu Pro Glu Arg Lys Phe Gly Val Val Val Val Gly Val 1 5 10 15 Gly Arg Ala Gly Ser Val Arg Met Arg Asp Leu Arg Asn Pro His Pro 20 25 30 Ser Ser Ala Phe Leu Asn Leu Ile Gly Phe Val Ser Arg Arg Glu Leu 35 40 45 Gly Ser Ile Asp Gly Val Gln Gln Ile Ser Leu Glu Asp Ala Leu Ser 50 55 60 Ser Gln Glu Val Glu Val Ala Tyr Ile Cys Ser Glu Ser Ser Ser Ser His 65 70 75 80 Glu Asp Tyr Ile Arg Gln Phe Leu Asn Ala Gly Lys His Val Leu Val 85 90 95 Glu Tyr Pro Met Thr Leu Ser Leu Ala Ala Ala Gln Glu Leu Trp Glu 100 105 110 Leu Ala Glu Gln Lys Gly Lys
  • residue 3 can be either alanine or threonine
  • residue 154 can be either alanine or serine
  • residue 155 can be either aspartic acid or glycine
  • residue 160 can be either aspartic acid or glutamic acid.
  • rat biliverdin reductase has an amino acid sequence corresponding to SEQ. ID. No. 4 as follows: Met Asp Ala Glu Pro Lys Arg Lys Phe Gly Val Val Val Val Gly Val 1 5 10 15 Gly Arg Ala Gly Ser Val Arg Leu Arg Asp Leu Lys Asp Pro Arg Ser 20 25 30 Ala Ala Phe Leu Asn Leu Ile Gly Phe Val Ser Arg Arg Glu Leu Gly 35 40 45 Ser Leu Asp Glu Val Arg Gln Ile Ser Leu Glu Asp Ala Leu Arg Ser 50 55 60 Gln Glu Ile Asp Val Ala Tyr Ile Cys Ser Glu Ser Ser Ser Ser His Glu 65 70 75 80 Asp Tyr Ile Arg Gln Phe Leu Gln Ala Gly Lys His Val Leu Val Glu 85 90 95 Tyr Pro Met Thr Leu Ser Phe Ala Ala Ala Gln Glu Leu Trp Glu Leu Trp Glu Le
  • rBVR Heterologous expression and isolation of rBVR is described in Fakhrai et al., J. Biol. Chem. 267(6):4023-4029 (1992), which is hereby incorporated by reference in its entirety.
  • the rBVR of SEQ. ID. No. 4 shares about 82% aa identity to the hBVR of SEQ. ID. No. 1, with variations in aa residues being highly conserved.
  • the DNA molecule encoding this form of rBVR has a nucleotide sequence corresponding to SEQ. ID. No.
  • hBVR of SEQ. ID. No. 1 is characterized by a number of functional domains, including putative and/or demonstrated phosphorylation sites from aa 15 to 20, aa 21 to 23, aa 44 to 46 or 47, aa 49 to 54, aa 58 to 61, aa 64 to 67, aa 78 to 81, aa 79 to 82, aa 189 to 192, aa 207 to 209, aa 214 to 217, aa 222 to 227, aa 236 to 241, aa 245 to 250, aa 267 to 269 or 270, and aa 294 to 296; a basic N-terminal domain characterized by aa 6 to 8; a hydrophobic domain characterized by aa 9 to 14 (FXVVVV, SEQ.
  • GLKRNRY nuclear localization signal spanning aa 222 to 228
  • PGLKR myristylation site spanning aa 221 to 225
  • HCX 10 CC zinc finger domain spanning aa 280 to 293
  • substrate binding domains including, without limitation, a protein kinase C (“PKC”) enhancing domain spanning aa 275 to 281 (KKRIXHC, SEQ. ID. No. 16) and a PKC inhibiting domain spanning aa 289 to 296 (QKXCXXXK, SEQ. ID. No. 17).
  • PKC protein kinase C
  • hBVR of SEQ. ID. No. 3 and rBVR of SEQ. ID. No. 4 include similar functional domains.
  • rBVR includes an identical hydrophobic domain, an identical nucleotide binding domain, an identical oxidoreductase domain, a conserved leucine zipper domain (with residue variations between L and K residues), identical or conserved kinase motifs, an identical nuclear localization signal, an identical myristylation site, a conserved zinc finger domain (with terminal C residue replaced by H), a conserved PKC enhancing domain, and a conserved PKC inhibiting domain.
  • DNA molecules encoding a BVR protein or polypeptide can also include a DNA molecule that hybridizes under stringent conditions to the DNA molecule having a nucleotide sequence of SEQ. ID. No. 2 or SEQ. ID. No. 5.
  • An example of suitable stringency conditions is when hybridization is carried out at a temperature of about 37° C. using a hybridization medium that includes 0.9M sodium citrate (“SSC”) buffer, followed by washing with 0.2 ⁇ SSC buffer at 37° C. Higher stringency can readily be attained by increasing the temperature for either hybridization or washing conditions or increasing the sodium concentration of the hybridization or wash medium.
  • SSC sodium citrate
  • Nonspecific binding may also be controlled using any one of a number of known techniques such as, for example, blocking the membrane with protein-containing solutions, addition of heterologous RNA, DNA, and SDS to the hybridization buffer, and treatment with RNase. Wash conditions are typically performed at or below stringency. Exemplary high stringency conditions include carrying out hybridization at a temperature of about 42° C. to about 65° C. for up to about 20 hours in a hybridization medium containing 1M NaCl, 50 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.1% sodium dodecyl sulfate (SDS), 0.2% ficoll, 0.2% polyvinylpyrrolidone, 0.2% bovine serum albumin, and 50 ⁇ g/ml E. coli DNA, followed by washing carried out at between about 42° C. to about 65° C. in a 0.2 ⁇ SSC buffer.
  • SDS sodium dodecyl sulfate
  • the BVR protein or polypeptide can also be a fragment of the above biliverdin reductase proteins or polypeptides or a variant thereof.
  • Fragments of BVR preferably contain one or more of the above-listed functional domains, and possess one or more of the activities of full length BVR. Suitable fragments can be produced by several means. Subclones of a gene encoding a known BVR can be produced using conventional molecular genetic manipulation for sub cloning gene fragments, such as described by Sambrook et al., Molecular Cloning: A Laboratory Manual , Cold Springs Laboratory, Cold Springs Harbor, N.Y. (1989), and Ausubel et al. (ed.), Current Protocols in Molecular Biology , John Wiley & Sons (New York, N.Y.) (1999 and preceding editions), each of which is hereby incorporated by reference in its entirety.
  • the subclones then are expressed in vitro or in vivo in bacterial cells to yield a smaller protein or polypeptide that can be tested for a particular activity, e.g., converting biliverdin to bilirubin, modifying cell structure, etc., as discussed infra. See also Huang et al., J. Biol. Chem. 264:7844-7849 (1989), which is hereby incorporated by reference in its entirety.
  • fragments of a BVR gene may be synthesized using the PCR technique together with specific sets of primers chosen to represent particular portions of the protein.
  • primers chosen to represent particular portions of the protein.
  • oligomers of at least about 15 to 20 nt in length can be selected from the nucleic acid molecules of SEQ. ID. No. 2 and SEQ ID. No. 5 for use as primers.
  • Variants of suitable BVR proteins or polypeptides can also be expressed. Variants may be made by, for example, the deletion, addition, or alteration of amino acids that have either (i) minimal influence on certain properties, secondary structure, and hydropathic nature of the polypeptide or (ii) substantial effect on one or more properties of BVR. Variants of BVR can also be fragments of BVR which include one or more deletion, addition, or alteration of amino acids of the type described above.
  • the BVR variant preferably contains a deletion, addition, or alteration of amino acids within one of the above-listed functional domains.
  • the substituted or additional amino acids can be either L-amino acids, D-amino acids, or modified amino acids, preferably L-amino acids.
  • Whether a substitution, addition, or deletion results in modification of BVR variant activity may depend, at least in part, on whether the altered amino acid is conserved.
  • conserved amino acids can be grouped either by molecular weight or charge and/or polarity of R groups, acidity, basicity, and presence of phenyl groups, as is known in the art.
  • Variants may also include, for example, a polypeptide conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein.
  • the polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification, identification, or therapeutic use (i.e., delivery) of the polypeptide.
  • the BVR protein or polypeptide can be recombinantly produced, isolated, and then purified, if necessary.
  • the biliverdin reductase protein or polypeptide is expressed in a recombinant host cell, typically, although not exclusively, a prokaryote.
  • the promoter region used to construct the recombinant DNA molecule i.e., transgene
  • Eukaryotic promoters and accompanying genetic signals may not be recognized in or may not function in a prokaryotic system, and, further, prokaryotic promoters are not recognized and do not function in eukaryotic cells.
  • SD Shine-Dalgarno
  • Promoters vary in their “strength” (i.e., their ability to promote transcription). For the purposes of expressing a cloned gene, it is desirable to use strong promoters in order to obtain a high level of transcription and, hence, expression of the gene. Depending upon the host cell system utilized, any one of a number of suitable promoters may be used. For instance, when cloning in E.
  • promoters such as the T7 phage promoter, lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, the P R and P L promoters of coliphage lambda and others, including but not limited, to lacUV5, ompF, bla, lpp, and the like, may be used to direct high levels of transcription of adjacent DNA segments. Additionally, a hybrid trp-lacUV5 (tac) promoter or other E. coli promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted gene.
  • trp-lacUV5 (tac) promoter or other E. coli promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted gene.
  • Bacterial host cell strains and expression vectors may be chosen which inhibit the action of the promoter unless specifically induced.
  • the addition of specific inducers is necessary for efficient transcription of the inserted DNA.
  • the lac operon is induced by the addition of lactose or IPTG (isopropylthio-beta-D-galactoside).
  • IPTG isopropylthio-beta-D-galactoside.
  • Specific initiation signals are also required for efficient gene transcription and translation in prokaryotic cells. These transcription and translation initiation signals may vary in “strength” as measured by the quantity of gene specific messenger RNA and protein synthesized, respectively.
  • the DNA expression vector which contains a promoter, may also contain any combination of various “strong” transcription and/or translation initiation signals. For instance, efficient translation in E. coli requires a Shine-Dalgarno (“SD”) sequence about 7-9 bases 5′ to the initiation codon (“ATG”) to provide a ribosome binding site. Thus, any SD-ATG combination that can be utilized by host cell ribosomes may be employed.
  • Such combinations include, but are not limited to, the SD-ATG combination from the cro gene or the N gene of coliphage lambda, or from the E. coli tryptophan E, D, C, B or A genes. Additionally, any SD-ATG combination produced by recombinant DNA or other techniques involving incorporation of synthetic nucleotides may be used.
  • Mammalian cells can also be used to recombinantly produce BVR or fragments or variants thereof.
  • Suitable mammalian host cells include, without limitation: COS (e.g., ATCC No. CRL 1650 or 1651), BHK (e.g., ATCC No. CRL 6281), CHO (ATCC No. CCL 61), HeLa (e.g., ATCC No. CCL 2), 293 (ATCC No. 1573), CHOP, and NS-1 cells.
  • Suitable expression vectors for directing expression in mammalian cells generally include a promoter, as well as other transcription and translation control sequences known in the art. Common promoters include, without limitation, SV40, MMTV, metallothionein-1, adenovirus Ela, CMV, immediate early, immunoglobulin heavy chain promoter and enhancer, and RSV-LTR.
  • DNA molecule coding for a biliverdin reductase protein or polypeptide, or fragment or variant thereof has been ligated to its appropriate regulatory regions using well known molecular cloning techniques, it can then be introduced into a suitable vector or otherwise introduced directly into a host cell using transformation protocols well known in the art (Sambrook et al., Molecular Cloning: A Laboratory Manual , Second Edition, Cold Spring Harbor Press, NY (1989), which is hereby incorporated by reference in its entirety).
  • the recombinant molecule can be introduced into host cells via transformation, particularly transduction, conjugation, mobilization, or electroporation.
  • Suitable host cells include, but are not limited to, bacteria, virus, yeast, mammalian cells, insect, plant, and the like.
  • the host cells when grown in an appropriate medium, are capable of expressing the biliverdin reductase, or fragment or variant thereof, which can then be isolated therefrom and, if necessary, purified.
  • the BVR, or fragment or variant thereof is preferably produced in purified form (preferably at least about 60%, more preferably 80%, pure) by conventional techniques.
  • the treated cell is preferably in vivo and the protein or polypeptide or RNA molecule is delivered into the cell in a manner which affords the protein or polypeptide or RNA molecule to be active within the cell.
  • a number of known delivery techniques can be utilized for the delivery, into cells, of either proteins or polypeptides or RNA, or DNA molecules encoding them.
  • a cell i.e., to be treated
  • a protein or polypeptide or RNA molecule it is preferred that the contacting be carried out by delivery of the protein or polypeptide or RNA molecule into the cell.
  • liposomes One approach for delivering protein or polypeptides or RNA molecules into cells involves the use of liposomes. Basically, this involves providing a liposome which includes that protein or polypeptide or RNA to be delivered, and then contacting the target cell with the liposome under conditions effective for delivery of the protein or polypeptide or RNA into the cell.
  • Liposomes are vesicles comprised of one or more concentrically ordered lipid bilayers which encapsulate an aqueous phase. They are normally not leaky, but can become leaky if a hole or pore occurs in the membrane, if the membrane is dissolved or degrades, or if the membrane temperature is increased to the phase transition temperature.
  • Current methods of drug delivery via liposomes require that the liposome carrier ultimately become permeable and release the encapsulated drug at the target site. This can be accomplished, for example, in a passive manner wherein the liposome bilayer degrades over time through the action of various agents in the body. Every liposome composition will have a characteristic half-life in the circulation or at other sites in the body and, thus, by controlling the half-life of the liposome composition, the rate at which the bilayer degrades can be somewhat regulated.
  • active drug release involves using an agent to induce a permeability change in the liposome vesicle.
  • Liposome membranes can be constructed so that they become destabilized when the environment becomes acidic near the liposome membrane (see, e.g., Proc. Natl. Acad. Sci. USA 84:7851 (1987); Biochemistry 28:908 (1989), which is hereby incorporated by reference in its entirety).
  • liposomes When liposomes are endocytosed by a target cell, for example, they can be routed to acidic endosomes which will destabilize the liposome and result in drug release.
  • the liposome membrane can be chemically modified such that an enzyme is placed as a coating on the membrane which slowly destabilizes the liposome. Since control of drug release depends on the concentration of enzyme initially placed in the membrane, there is no real effective way to modulate or alter drug release to achieve “on demand” drug delivery. The same problem exists for pH-sensitive liposomes in that as soon as the liposome vesicle comes into contact with a target cell, it will be engulfed and a drop in pH will lead to drug release.
  • This liposome delivery system can also be made to accumulate at a target organ, tissue, or cell via active targeting (e.g., by incorporating an antibody or hormone on the surface of the liposomal vehicle). This can be achieved according to known methods.
  • the chimeric protein can include a ligand domain and, e.g., BVR or a fragment or variant thereof.
  • the ligand domain is specific for receptors located on a target cell.
  • DNA molecules encoding the desired protein or polypeptide or RNA can be delivered into the cell.
  • this includes providing a nucleic acid molecule encoding the protein or polypeptide and then introducing the nucleic acid molecule into the cell under conditions effective to express the protein or polypeptide or RNA in the cell.
  • this is achieved by inserting the nucleic acid molecule into an expression vector before it is introduced into the cell.
  • an adenovirus vector When transforming mammalian cells for heterologous expression of a protein or polypeptide, an adenovirus vector can be employed.
  • Adenovirus gene delivery vehicles can be readily prepared and utilized given the disclosure provided in Berkner, Biotechniques 6:616-627 (1988) and Rosenfeld et al., Science 252:431-434 (1991), WO 93/07283, WO 93/06223, and WO 93/07282, each of which is hereby incorporated by reference in its entirety.
  • Adeno-associated viral gene delivery vehicles can be constructed and used to deliver a gene to cells.
  • Retroviral vectors which have been modified to form infective transformation systems can also be used to deliver nucleic acid encoding a desired protein or polypeptide or RNA product into a target cell.
  • One such type of retroviral vector is disclosed in U.S. Pat. No. 5,849,586 to Kriegler et al., which is hereby incorporated by reference in its entirety.
  • infective transformation system it can be targeted for delivery of the nucleic acid to a specific cell type.
  • a high titer of the infective transformation system can be injected directly within the desired site so as to enhance the likelihood of cell infection within the desired site.
  • the infected cells will then express the desired protein product, in this case BVR, or fragments or variants thereof, to modify the structure of those cells which have been infected.
  • proteins or polypeptides or nucleic acids are administered alone or in combination with pharmaceutically or physiologically acceptable carriers, excipients, or stabilizers, or in solid or liquid form such as, tablets, capsules, powders, solutions, suspensions, or emulsions, they can be administered orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes, such as, that of the nose, throat, and bronchial tubes.
  • the proteins or polypeptides or nucleic acids can be administered intravenously.
  • solutions or suspensions of these materials can be prepared in a physiologically acceptable diluent with a pharmaceutical carrier.
  • a pharmaceutical carrier include sterile liquids, such as water and oils, with or without the addition of a surfactant and other pharmaceutically and physiologically acceptable carrier, including adjuvants, excipients or stabilizers.
  • sterile liquids such as water and oils
  • surfactant and other pharmaceutically and physiologically acceptable carrier including adjuvants, excipients or stabilizers.
  • Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil.
  • water, saline, aqueous dextrose and related sugar solution, and glycols, such as propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions.
  • the proteins or polypeptides or nucleic acids in solution or suspension may be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants.
  • suitable propellants for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants.
  • the materials of the present invention also may be administered in a non-pressurized form such as in a nebulizer or atomizer.
  • Both the biliverdin reductase and fragments or variants thereof can be delivered to the target cells (i.e., at or around the site where cell modification is desired) using the above-described methods for delivering such therapeutic products.
  • the target cells i.e., at or around the site where cell modification is desired
  • the blood-brain barrier typically prevents many compounds in the blood stream from entering the tissues and fluids of the brain. Nature provides this mechanism to insure a toxin-free environment for neurologic function. However, it also prevents delivery to the brain of compounds, in this case neuroprotective compounds that can inhibit nerve cell death following an ischemic event.
  • the blood-brain barrier is temporarily “opened” by targeting a selected location in the brain and applying ultrasound to induce, in the central nervous system (CNS) tissues and/or fluids at that location, a change detectable by imaging.
  • CNS central nervous system
  • a protein or polypeptide or RNA molecule of the present invention can be delivered to the targeted region of the brain while the blood-brain barrier remains “open,” allowing targeted neuronal cells to uptake the delivered protein or polypeptide or RNA.
  • At least a portion of the brain in the vicinity of the selected location can be imaged, e.g., via magnetic resonance imaging, to confirm the location of the change.
  • Alternative approaches for negotiating the blood-brain barrier include chimeric peptides and modified liposome structures which contain a PEG moiety (reviewed in Pardridge, J. Neurochem. 70:1781-1792 (1998), which is hereby incorporated by reference in its entirety), as well as osmotic opening (i.e., with bradykinin, mannitol, RPM7, etc.) and direct intracerebral infusion (Kroll et al., Neurosurgery 42(5):1083-1100 (1998), which is hereby incorporated by reference in its entirety).
  • rBVR Analysis of the promoter region associated with the nucleic acid encoding rBVR indicates the presence of recognition sites for several regulating proteins, including INF-1, an enhancer of cytokine and virus-induced transcriptional activation, and AP-1, the proto-oncogene binding site (McCoubrey et al., “The Structure, Organization and Differential Expression of the Rat Gene Encoding Biliverdin Reductase,” Gene 160:235-240 (1995), which is hereby incorporated by reference in its entirety. Also, two elements known to be involved in embryonic gene expression, P3A and engrailed, are present in the promoter region of this gene. These criteria are consistent with the function of BVR in a regulatory capacity in the cell.
  • one aspect of the present invention relates to a method of modifying cell structure which includes: increasing the intracellular concentration of biliverdin reductase, or a fragment or variant thereof, in a mammalian cell under conditions effective to modify the structure of the mammalian cell.
  • biliverdin reductase may increase some basal level of biliverdin reductase in the cell which has been targeted.
  • the increase in biliverdin reductase intracellular concentration is simply the result of causing more biliverdin reductase to be expressed (e.g., inducing or transforming) or introducing additional biliverdin reductase from an external source (i.e., administration).
  • any increase in biliverdin reductase fragments or variants is the result of their heterologous expression (i.e., transforming) or introducing biliverdin reductase fragments or variants from an external source (i.e., administering).
  • the increase in concentration can be achieved by introducing the BVR or BVR fragments or variants into the cell. Typically, this is done by contacting the mammalian cell (to be modified) with a delivery vehicle which includes biliverdin reductase or a fragment or variant thereof.
  • the delivery vehicle can be any delivery vehicle of the type described above for protein delivery.
  • Such increase in cellular concentration can be achieved by heterologous expression by the mammalian cell (to be modified).
  • heterologous expression is typically the result of transforming the mammalian cell with a nucleic acid encoding biliverdin reductase or a fragment or variant thereof under conditions effective for expression of the biliverdin reductase or the fragment or variant thereof in the mammalian cell.
  • the transformation can be achieved using any nucleic acid delivery system of the type described above. (e.g., infective transformation).
  • the mammalian cells which can be treated include, without limitation, stem cells (both omnipotent and pluripotent stem cells), neuronal or glial cells, vascular smooth muscle cells, skeletal muscle cells, epithelial cells, and nucleated blood cells (e.g., macrophages and other blood cells).
  • stem cells both omnipotent and pluripotent stem cells
  • neuronal or glial cells vascular smooth muscle cells
  • skeletal muscle cells skeletal muscle cells
  • epithelial cells e.g., macrophages and other blood cells
  • nucleated blood cells e.g., macrophages and other blood cells.
  • Exemplary aspects of the mammalian cell structure which can be modified in accordance with the present invention include, without limitation, enhanced cell size (i.e., forming giant cells), actin microspike formation, polar cell morphology (i.e., with protracted filopodia extensions), and a combination thereof.
  • enhanced cell size i.e., forming giant cells
  • actin microspike formation i.e., actin microspike formation
  • polar cell morphology i.e., with protracted filopodia extensions
  • modified cell structure is the result of biliverdin reductase interaction with proteins and kinases that govern cell cycling and with polypeptide growth factors.
  • the present invention can be utilized to perform organogenesis, tissue remodeling, wound healing, angiogenesis, or combinations thereof.
  • Tissue remodeling of course, encompasses both wound healing and angiogenesis.
  • a further aspect of the present invention relates to a method of performing in vivo tissue remodeling in a mammal.
  • This aspect of the invention includes: delivering biliverdin reductase, or fragments or variants thereof, to one or more cells present at a site of tissue remodeling in a mammal, wherein the delivering (of BVR or its fragments or variants) increases the intracellular concentration of biliverdin reductase, or fragments or variants thereof, under conditions effective to modify the structure of the one or more cells at the site of tissue remodeling, thereby remodeling the tissue containing the one or more cells.
  • Tissues which can be remodeled in vivo include, without limitation, epithelial tissues, nerve tissues, muscular tissues (both smooth muscle and skeletal muscle tissues), or connective tissue. More specifically, angiogenesis can implicate remodeling of vascular tissue and modifying the structure of vascular smooth muscle, bladder, and urinary tract cells. Likewise, wound healing can implicate remodeling of epithelial tissues, nerve tissues, muscular tissues (both smooth muscle and skeletal muscle tissues), or connective tissues via modifying the structures of epithelial cells, nerve or glial cells, vascular and skeletal muscle cells, etc.
  • tissue remodeling where multiple tissues are remodeled
  • tissue remodeling it also contemplated to utilize the present invention according to a method of repairing a damaged organ or organ system by performing the method of in vivo tissue remodeling in accordance with the present invention, where the site of tissue remodeling is within the damaged organ or organ system.
  • exemplary organ or organ systems which can be subject to repair include, without limitation, skin, liver, nervous system (e.g., both sensory neurons and motor neurons), cardiovascular system, and urogenital tract.
  • Open cutaneous wounds represent one major category of wounds and include burn wounds, neuropathic ulcers, pressure sores, venous stasis ulcers, and diabetic ulcers. Open cutaneous wounds routinely heal by a process which comprises six major components: i) inflammation, ii) fibroblast proliferation, iii) blood vessel proliferation, iv) connective tissue synthesis v) epithelialization, and vi) wound contraction. Wound healing is impaired when these components, either individually or as a whole, do not function properly.
  • agents which promote a more rapid influx of fibroblasts, endothelial and epithelial cells into wounds should increase the rate at which wounds heal.
  • agents which promote a more rapid influx of fibroblasts, endothelial and epithelial cells into wounds should increase the rate at which wounds heal.
  • biliverdin reductase By virtue of increasing the intracellular concentration of biliverdin reductase, it becomes possible to induce an increase in cell size, the formation of actin microspikes, and morphological changes in cell polarity, i.e., formation of filopodia extensions.
  • BVR for wound healing
  • a medicament selected from the group consisting of an antibacterial agent, an antiviral agent, an antifungal agent, an antiparasitic agent, an anti-inflammatory agent, an analgesic agent, an antipruritic agent, or a combination thereof
  • a preferred mode of administration is by the topical route.
  • HeLa cells were transfected in vitro with biliverdin reductase encoding DNA.
  • a HeLa cell suspension having a density of about 12 ⁇ 10 4 /ml was introduced to a 12-well plate using 0.2 ml of the cell suspension per well (i.e., about 2.4 ⁇ 10 4 cells per well). The following protocol was employed for transfection:
  • cells were immunostained using the following protocol. HeLa cells were washed once for 5 min in PBS (0.1% PB, 0.9% NaCl), followed by treatment with 4% PFA (on ice). 10 min later, cells were washed 3 times for 5 min each time in PBS. Cells were blocked by treatment with PBS (950 ⁇ l)+50 ⁇ l horse serum (5% HS PBS) for 1 h at room temperature. Cells were treated with a solution of 3% HS-0.25% Triton-PBS at 4° C. overnight, thereafter cells were treated with 1:1000 dilution of BVR antibody.
  • PBS 950 ⁇ l
  • horse serum 5% HS PBS
  • cells were washed 3 times for 5 min each time in PBS—0.25% Triton ⁇ 100 and treated with second antibody solution consisting of: horse serum, 15 ⁇ l/ml and antimouse-IgG, 5 ⁇ l/ml. After 3 times washing with PBS for 5 min each time, cells were visualized using ABC solution (Vector Labs) and stained for 30 min.
  • PBS 0.25% Triton ⁇ 100
  • second antibody solution consisting of: horse serum, 15 ⁇ l/ml and antimouse-IgG, 5 ⁇ l/ml. After 3 times washing with PBS for 5 min each time, cells were visualized using ABC solution (Vector Labs) and stained for 30 min.
  • Control and transformed HeLa cells were visualized by immunostaining using antibody to BVR. As shown in FIGS. 1-6 , the transformed HeLa cells displayed larger cell size relative to control cells, formation of actin microspikes, and polar cell morphology with filopodia extensions.
  • BVR is a regulator of cell proliferation and cell differentiation.
  • transfected cells Following transformation to induce an increase in BVR expression, transfected cells were transformed into giant cells several times the size of normal cells. Moreover, the transfected cells displayed formation of actin microspikes. Such actin microspikes are known to act as sensory devices by which cells explore their environment.
  • BVR transfected cells exhibited polar cell morphology, as characterized by protracted filopodia extensions that resemble that of neuronal axon and dendritic extensions, a phenotype which is not displayed by Cdc42 transfected cells (Adams and Schwarz, “Stimulation of Fasein Spikes by Thrombospondin-1 is Mediated by GTPases Rac and Cdc42 ,” J. Cell Biol. 150:807-822 (2000), which is hereby incorporated by reference in its entirety). These properties are displayed by certain cyclin-dependent kinases.
  • Cdc42 kinase stimulates spike formation (Kozma et al., “The Ras-related protein Cdc42Hs and Bradykinin Promote Formation of Peripheral Actin Microspikes and Filopodia in Swiss 3T3 Fibroblasts,” Mol. Cell Biol. 15:1942-1952 (1995); Nobes and Hall, “Rho, Rac, and Cdc42 GTPases Regulate the Assembly of Multimolecular Focal Complexes Associated with Actin Stress Fibers, Lamellipodia, and Filopodia,” Cell 81:53-62 (1995); Adams and Schwarz, “Stimulation of Fasein Spikes by Thrombospondin-1 is Mediated by GTPases Rac and Cdc42 ,” J.
  • D type cyclins e.g., cyclin D 2
  • D type cyclins deregulate cell size and cause cell mass increase
  • Kershoff and Ziff “Cyclin D 2 Ha-Ras Transformed Rat Embryo Fibroblasts Exhibit Novel Deregulation of Cell Size Control and Early S Phase Arrest in Low Serum,” EMBO J. 14:1892-1903 (1995), which is hereby incorporated by reference in its entirety).
  • GTPases Rac/Ha-Ras
  • Adams and Schwarz “Stimulation of Fasein Spikes by Thrombospondin-1 is Mediated by GTPases Rac and Cdc42 ,” J. Cell Biol. 150:807-822 (2000); Kershoff and Ziff, “Cyclin D 2 and Ha-Ras Transformed Rat Embryo Fibroblasts Exhibit Novel Deregulation of Cell Size Control and Early S Phase Arrest in Low Serum,” EMBO J. 14:1892-1903 (1995), each of which is hereby incorporated by reference in its entirety).
  • BVR is a protein kinase and has both cell proliferating and cell differentiation activities. Furthermore, BVR can unexpectedly control the cell size under normal conditions, whereas cyclin D 2 and Ha-Ras transformed cells only display giant size in low serum conditions. The morphology of the above-described transformed cells is also consistent with the use of BVR expression for promoting axonal growth in the case of nerve damage.
  • X is used to depict a residue which can be any naturally occurring amino acid, unless otherwise indicated.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Disclosed is a method of modifying cell structure which includes: increasing the intracellular concentration of biliverdin reductase, or a fragment or variant thereof, in a mammalian cell under conditions effective to modify the structure of the mammalian cell. Also disclosed are methods of performing in vivo tissue remodeling in a mammal and repairing a damaged organ or organ system, both of which include delivering biliverdin reductase, or fragments or variants thereof, to one or more cells present at a site of tissue remodeling in a mammal, wherein said delivering increases the intracellular concentration of biliverdin reductase, or fragments or variants thereof, under conditions effective to modify the structure of the one or more cells at the site of tissue remodeling, thereby remodeling the tissue containing the one or more cells.

Description

  • This application is a divisional application of U.S. patent application Ser. No. 10/045,545 filed Jan. 14, 2002, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/261,500, filed Jan. 12, 2001, each of which is hereby incorporated by reference in its entirety.
  • This work was supported by the U.S. National Institutes of Health under Grant Nos. ES04066 and ES04391. The U.S. Government may have certain rights in the invention.
    • FIELD OF THE INVENTION
  • The present invention relates to methods of modifying cell structure and remodeling tissue which involve modulating the intracellular levels of biliverdin reductase or active fragments or variants thereof.
    • BACKGROUND OF THE INVENTION
  • Biliverdin reductase (“BVR”) catalyzes reduction of the γ-meso bridge of biliverdin, an open tetrapyrrole, to produce bilirubin (Singleton et al., J. Biol. Chem. 240: 47890-4789 (1965); Tenhunen et al., Biochemistry 9:298-303 (1970); Colleran et al., Biochem J. 119:16P-19P (1970); Kutty et al., J. Biol. Chem. 256:3956-3962 (1981); Buldain et al., Eur. J. Biochem. 156:179-184 (1986); Noguchi et al., Biochem J. 86:833-839 (1989)). In mammals, the oxidative cleavage of heme is catalyzed by the heme oxygenase system (Maines, Ann. Rev. Pharmacol. Toxicol. 37:517-554 (1997)). Because open tetrapyrroles are generally believed to be devoid of biological functions, the enzymes that catalyze their formation have not traditionally been in the main stream of research activity. In plants, however, biliverdin analogues, phytochromobilins, function in photoregulatory capacity (Terry et al., J. Biol. Chem. 266:22215-22221 (1991); Cornejo et al., J. Biol. Chem. 267:14790-14798 (1992)). Molecular cloning and biochemical analyses have shown that the enzyme, which in human is a 296 residue polypeptide, is highly conserved both at its primary structure and at its unique catalytic properties (Fakhrai et al., J. Biol. Chem. 267:4023-4029 (1992); McCoubrey et al., Eur. J Biochem. 222:597-603 (1994); McCoubrey et al., Gene 160:235-240 (1995); Maines et al., Eur. J. Biochem. 235:372-381 (1996)). BVR is the only enzyme described to date with dual pH/dual adenine nucleotide cofactor requirements (Kutty et al., J. Biol. Chem. 256:3956-3962 (1981); Fakhrai et al., J. Biol. Chem. 267:4023-4029 (1992); Maines et al., Eur. J. Biochem. 235:372-381 (1996); Huang et al., J. Biol. Chem. 264:7844-7849 (1989)). The reductase uses NADH in the acidic range (optimum range ˜pH 6.0-6.7), whereas NADPH is utilized in the basic range (optimum range ˜pH 8.5-8.7). BVR, which is a zinc metalloprotein (Maines et al., Eur. J. Biochem. 235:372-381 (1996)), possesses a HCX10CH or HCX10CC motif in the carboxy terminal third of the protein, which is similar to the zinc binding motif of protein kinase C (Hubbard et al., Science 254:1776-1779 (1991)) and may be the site of interaction of BVR with zinc.
  • BVR was previously thought to be simply a house-keeping enzyme found in most mammalian cells in excess of, or in disproportionate levels to, heme oxygenase isozymes (Ewing et al., J. Neurochem. 61:1015-1023 (1993)). Yet it has the above-noted noted unique and uncommon properties. Examination of the primary structure of human BVR, which recently became available (Maines et al., Eur. J. Biochem. 235:372-381 (1996)), revealed the presence of consensus sequences that are conserved in protein kinases, the most notable one being the GXGXXG motif near the N terminus of the protein that is found invariably in all kinases (Kamps et al., Nature 310:589-592 (1984); Hunter et al., Ann. Rev. Biochem. 54:897-930 (1985); Schlessinger, Trend. Biochem. Sci. 13:443-447 (1988); Hanks et al., Science 241:42-52 (1988); Yarden et al., Annu. Rev. Biochem. 57:443-478 (1988); Hanks et al., Methods Enzymol. 200:38-62 (1991)). A valine residue is present in BVR just 2 positions downstream from the last glycine of this motif. A valine residue is invariant at the corresponding position, as in BVR, in the family of kinases that phosphorylate G-protein coupled receptors (Garcia-Bustos et al., Biochim. Biophys. ACTA 1071:83-101 (1991)). Database search results also identified additional similarities with PKGs, including a cluster of charged residues (KRNR) in the carboxy terminus of BVR. Such clusters are a characteristic of the nuclear localization signal (“NLS”) (Garcia-Bustos et al., Biochim. Biophys. ACTA 1071:83-101 (1991)).
  • Although BVR has previously been identified as exhibiting protective effects against oxidative stress and as sharing characteristics with known kinases (see U.S. patent application Ser. No. 09/606,129 to Maines, filed Jun. 28, 2000), it is unclear the extent to which BVR is implicated in cellular repair mechanisms. The present invention is directed to overcoming the above-identified deficiencies in the art.
    • SUMMARY OF THE INVENTION
  • A first aspect of the present invention relates to a method of modifying cell structure which includes: increasing the intracellular concentration of biliverdin reductase, or a fragment or variant thereof, in a mammalian cell under conditions effective to modify the structure of the mammalian cell.
  • A second aspect of the present invention relates to a method of in vivo tissue remodeling in a mammal which includes: delivering biliverdin reductase, or fragments or variants thereof, to one or more cells present at a site of tissue remodeling in a mammal, wherein said delivering increases the intracellular concentration of biliverdin reductase, or fragments or variants thereof, under conditions effective to modify the structure of the one or more cells at the site of tissue remodeling, thereby remodeling the tissue containing the one or more cells.
  • A third aspect of the present invention relates to a method of repairing a damaged organ or organ system by performing the in vivo tissue modeling of the present invention, where the site of tissue remodeling is within the damaged organ or organ system.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1-6 show different images of HeLa cells transfected with human BVR DNA. Differences between untransfected cells (normal morphology) and transfected cells (immunostained) is readily apparent. The transfected cells show remarkable enlargement, altered cellular morphology including filopodia, and the appearance of spikes which are clearly observed.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The methods of modifying cell structure and remodeling tissue according to the present invention involve modulating the intracellular levels of biliverdin reductase (“BVR”) or active fragments thereof. Modulating intracellular levels of BVR can be achieved using known recombinant techniques directed to cells or tissues to be affected, as described below, or by using known protein delivery techniques for delivering BVR into cells or tissues to be affected.
  • One form of human biliverdin reductase (“hBVR”) has an amino acid sequence corresponding to SEQ. ID. No. 1 as follows:
    Met Asn Ala Glu Pro Glu Arg Lys Phe Gly Val Val Val Val Gly Val
    1 5 10 15
    Gly Arg Ala Gly Ser Val Arg Met Arg Asp Leu Arg Asn Pro His Pro
    20 25 30
    Ser Ser Ala Phe Leu Asn Leu Ile Gly Phe Val Ser Arg Arg Glu Leu
    35 40 45
    Gly Ser Ile Asp Gly Val Gln Gln Ile Ser Leu Glu Asp Ala Leu Ser
    50 55 60
    Ser Gln Glu Val Glu Val Ala Tyr Ile Cys Ser Glu Ser Ser Ser His
    65 70 75 80
    Glu Asp Tyr Ile Arg Gln Phe Leu Asn Ala Gly Lys His Val Leu Val
    85 90 95
    Glu Tyr Pro Met Thr Leu Ser Leu Ala Ala Ala Gln Glu Leu Trp Glu
    100 105 110
    Leu Ala Glu Gln Lys Gly Lys Val Leu His Glu Glu His Val Glu Leu
    115 120 125
    Leu Met Glu Glu Phe Ala Phe Leu Lys Lys Glu Val Val Gly Lys Asp
    130 135 140
    Leu Leu Lys Gly Ser Leu Leu Phe Thr Ser Asp Pro Leu Glu Glu Asp
    145 150 155 160
    Arg Phe Gly Phe Pro Ala Phe Ser Gly Ile Ser Arg Leu Thr Trp Leu
    165 170 175
    Val Ser Leu Phe Gly Glu Leu Ser Leu Val Ser Ala Thr Leu Glu Glu
    180 185 190
    Arg Lys Glu Asp Gln Tyr Met Lys Met Thr Val Cys Leu Glu Thr Glu
    195 200 205
    Lys Lys Ser Pro Leu Ser Trp Ile Glu Glu Lys Gly Pro Gly Leu Lys
    210 215 220
    Arg Asn Arg Tyr Leu Ser Phe His Phe Lys Ser Gly Ser Leu Glu Asn
    225 230 235 240
    Val Pro Asn Val Gly Val Asn Lys Asn Ile Phe Leu Lys Asp Gln Asn
    245 250 255
    Ile Phe Val Gln Lys Leu Leu Gly Gln Phe Ser Glu Lys Glu Leu Ala
    260 265 270
    Ala Glu Lys Lys Arg Ile Leu His Cys Leu Gly Leu Ala Glu Glu Ile
    275 280 285
    Gln Lys Tyr Cys Cys Ser Arg Lys
    290 295
  • Heterologous expression and isolation of hBVR is described in Maines et al., Eur. J. Biochem. 235(1-2):372-381 (1996); Maines et al., Arch. Biochem. Biophys. 300(1):320-326 (1993), each of which is hereby incorporated by reference in its entirety. The DNA molecule encoding this form of hBVR has a nucleotide sequence corresponding to SEQ. ID. No. 2 as follows:
    ggggtggcgc ccggagctgc acggagagcg tgcccgtcag tgaccgaaga agagaccaag 60
    atgaatgcag agcccgagag gaagtttggc gtggtggtgg ttggtgttgg ccgagccggc 120
    tccgtgcgga tgagggactt gcggaatcca cacccttcct cagcgttcct gaacctgatt 180
    ggcttcgtgt cgagaaggga gctcgggagc attgatggag tccagcagat ttctttggag 240
    gatgctcttt ccagccaaga ggtggaggtc gcctatatct gcagtgagag ctccagccat 300
    gaggactaca tcaggcagtt ccttaatgct ggcaagcacg tccttgtgga ataccccatg 360
    acactgtcat tggcggccgc tcaggaactg tgggagctgg ctgagcagaa aggaaaagtc 420
    ttgcacgagg agcatgttga actcttgatg gaggaattcg ctttcctgaa aaaagaagtg 480
    gtggggaaag acctgctgaa agggtcgctc ctcttcacat ctgacccgtt ggaagaagac 540
    cggtttggct tccctgcatt cagcggcatc tctcgactga cctggctggt ctccctcttt 600
    ggggagcttt ctcttgtgtc tgccactttg gaagagcgaa aggaagatca gtatatgaaa 660
    atgacagtgt gtctggagac agagaagaaa agtccactgt catggattga agaaaaagga 720
    cctggtctaa aacgaaacag atatttaagc ttccatttca agtctgggtc cttggagaat 780
    gtgccaaatg taggagtgaa taagaacata tttctgaaag atcaaaatat atttgtccag 840
    aaactcttgg gccagttctc tgagaaggaa ctggctgctg aaaagaaacg catcctgcac 900
    tgcctggggc ttgcagaaga aatccagaaa tattgctgtt caaggaagta agaggaggag 960
    gtgatgtagc acttccaaga tggcaccagc atttggttct tctcaagagt tgaccattat 1020
    ctctattctt aaaattaaac atgttgggga aacaaaaaaa aaaaaaaaaa 1070

    The open reading frame which encodes hBVR of SEQ. ID. No. 1 extends from nt 1 to nt 888.
  • Another form of hBVR has an amino acid sequence according to SEQ. ID. No. 3 as follows:
    Met Asn Thr Glu Pro Glu Arg Lys Phe Gly Val Val Val Val Gly Val
    1 5 10 15
    Gly Arg Ala Gly Ser Val Arg Met Arg Asp Leu Arg Asn Pro His Pro
    20 25 30
    Ser Ser Ala Phe Leu Asn Leu Ile Gly Phe Val Ser Arg Arg Glu Leu
    35 40 45
    Gly Ser Ile Asp Gly Val Gln Gln Ile Ser Leu Glu Asp Ala Leu Ser
    50 55 60
    Ser Gln Glu Val Glu Val Ala Tyr Ile Cys Ser Glu Ser Ser Ser His
    65 70 75 80
    Glu Asp Tyr Ile Arg Gln Phe Leu Asn Ala Gly Lys His Val Leu Val
    85 90 95
    Glu Tyr Pro Met Thr Leu Ser Leu Ala Ala Ala Gln Glu Leu Trp Glu
    100 105 110
    Leu Ala Glu Gln Lys Gly Lys Val Leu His Glu Glu His Val Glu Leu
    115 120 125
    Leu Met Glu Glu Phe Ala Phe Leu Lys Lys Glu Val Val Gly Lys Asp
    130 135 140
    Leu Leu Lys Gly Ser Leu Leu Phe Thr Ala Gly Pro Leu Glu Glu Glu
    145 150 155 160
    Arg Phe Gly Phe Pro Ala Phe Ser Gly Ile Ser Arg Leu Thr Trp Leu
    165 170 175
    Val Ser Leu Phe Gly Glu Leu Ser Leu Val Ser Ala Thr Leu Glu Glu
    180 185 190
    Arg Lys Glu Asp Gln Tyr Met Lys Met Thr Val Cys Leu Glu Thr Glu
    195 200 205
    Lys Lys Ser Pro Leu Ser Trp Ile Glu Glu Lys Gly Pro Gly Leu Lys
    210 215 220
    Arg Asn Arg Tyr Leu Ser Phe His Phe Lys Ser Gly Ser Leu Glu Asn
    225 230 235 240
    Val Pro Asn Val Gly Val Asn Lys Asn Ile Phe Leu Lys Asp Gln Asn
    245 250 255
    Ile Phe Val Gln Lys Leu Leu Gly Gln Phe Ser Glu Lys Glu Leu Ala
    260 265 270
    Ala Glu Lys Lys Arg Ile Leu His Cys Leu Gly Leu Ala Glu Glu Ile
    275 280 285
    Gln Lys Tyr Cys Cys Ser Arg Lys
    290 295

    This hBVR sequence is reported at Komuro et al., NCBI Accession No. G02066, direct submission to the EMBL Data Library (1998), which is hereby incorporated by reference in its entirety. Differences between the hBVR of SEQ. ID. No. 1 and the hBVR of SEQ. ID. No. 3 are at aa residues 3, 154, 155, and 160. Thus, residue 3 can be either alanine or threonine, residue 154 can be either alanine or serine, residue 155 can be either aspartic acid or glycine, and residue 160 can be either aspartic acid or glutamic acid.
  • One form of rat biliverdin reductase (“rBVR”) has an amino acid sequence corresponding to SEQ. ID. No. 4 as follows:
    Met Asp Ala Glu Pro Lys Arg Lys Phe Gly Val Val Val Val Gly Val
      1               5                  10                  15
    Gly Arg Ala Gly Ser Val Arg Leu Arg Asp Leu Lys Asp Pro Arg Ser
                 20                  25                  30
    Ala Ala Phe Leu Asn Leu Ile Gly Phe Val Ser Arg Arg Glu Leu Gly
             35                  40                  45
    Ser Leu Asp Glu Val Arg Gln Ile Ser Leu Glu Asp Ala Leu Arg Ser
         50                  55                  60
    Gln Glu Ile Asp Val Ala Tyr Ile Cys Ser Glu Ser Ser Ser His Glu
     65                  70                  75                  80
    Asp Tyr Ile Arg Gln Phe Leu Gln Ala Gly Lys His Val Leu Val Glu
                     85                  90                  95
    Tyr Pro Met Thr Leu Ser Phe Ala Ala Ala Gln Glu Leu Trp Glu Leu
                100                 105                 110
    Ala Ala Gln Lys Gly Arg Val Leu His Glu Glu His Val Glu Leu Leu
            115                 120                 125
    Met Glu Glu Phe Glu Phe Leu Arg Arg Glu Val Leu Gly Lys Glu Leu
        130                 135                 140
    Leu Lys Gly Ser Leu Arg Phe Thr Ala Ser Pro Leu Glu Glu Glu Arg
    145                 150                 155                 160
    Phe Gly Phe Pro Ala Phe Ser Gly Ile Ser Arg Leu Thr Trp Leu Val
                    165                 170                 175
    Ser Leu Phe Gly Glu Leu Ser Leu Ile Ser Ala Thr Leu Glu Glu Arg
                180                 185                 190
    Lys Glu Asp Gln Tyr Met Lys Met Thr Val Gln Leu Glu Thr Gln Asn
            195                 200                 205
    Lys Gly Leu Leu Ser Trp Ile Glu Glu Lys Gly Pro Gly Leu Lys Arg
        210                 215                 220
    Asn Arg Tyr Val Asn Phe Gln Phe Thr Ser Gly Ser Leu Glu Glu Val
    225                 230                 235                 240
    Pro Ser Val Gly Val Asn Lys Asn Ile Phe Leu Lys Asp Gln Asp Ile
                    245                 250                 255
    Phe Val Gln Lys Leu Leu Asp Gln Val Ser Ala Glu Asp Leu Ala Ala
                260                 265                 270
    Glu Lys Lys Arg Ile Met His Cys Leu Gly Leu Ala Ser Asp Ile Gln
            275                 280                 285
    Lys Leu Cys His Gln Lys Lys
        290                 295
  • Heterologous expression and isolation of rBVR is described in Fakhrai et al., J. Biol. Chem. 267(6):4023-4029 (1992), which is hereby incorporated by reference in its entirety. The rBVR of SEQ. ID. No. 4 shares about 82% aa identity to the hBVR of SEQ. ID. No. 1, with variations in aa residues being highly conserved. The DNA molecule encoding this form of rBVR has a nucleotide sequence corresponding to SEQ. ID. No. 5 as follows:
    ggtcaacagc taagtgaagc catatccata gagagtttgt gccagtgccc caagatcctg 60
    aacctctgtc tgtcttcgga cactgactga agagaccgag atggatgccg agccaaagag 120
    gaaatttgga gtggtagtgg ttggtgttgg cagagctggc tcggtgaggc tgagggactt 180
    gaaggatcca cgctctgcag cattcctgaa cctgattgga tttgtgtcca gacgagagct 240
    tgggagcctt gatgaagtac ggcagatttc tttggaagat gctctccgaa gccaagagat 300
    tgatgtcgcc tatatttgca gtgagagttc cagccatgaa gactatatac ggcagtttct 360
    gcaggctggc aagcatgtcc tcgtggaata ccccatgaca ctgtcatttg cggcggccca 420
    ggagctgtgg gagctggccg cacagaaagg gagagtcctg catgaggagc acgtggaact 480
    cttgatggag gaattcgaat tcctgagaag agaagtgttg gggaaagagc tactgaaagg 540
    gtctcttcgc ttcacagcta gcccactgga agaagagaga tttggcttcc ctgcgttcag 600
    cggcatttct cgcctgacct ggctggtctc cctcttcggg gagctttctc ttatttctgc 660
    caccttggaa gagcgaaaag aggatcagta tatgaaaatg accgtgcagc tggagaccca 720
    gaacaagggt ctgctgtcat ggattgaaga gaaagggcct ggcttaaaaa gaaacagata 780
    tgtaaacttc cagttcactt ctgggtccct ggaggaagtg ccaagtgtag gggtcaataa 840
    gaacattttc ctgaaagatc aggatatatt tgttcagaag ctcttagacc aggtctctgc 900
    agaggacctg gctgctgaga agaagcgcat catgcattgc ctggggctgg ccagcgacat 960
    ccagaagctt tgccaccaga agaagtgaag aggaagcttc agagacttct gaagggggcc 1020
    agggtttggt cctatcaacc attcaccttt agctcttaca attaaacatg tcagataaac 1080
    a 1081

    The open reading frame which encodes rBVR of SEQ. ID. No. 4 extends from nt 1 to nt 885.
  • By way of example, hBVR of SEQ. ID. No. 1 is characterized by a number of functional domains, including putative and/or demonstrated phosphorylation sites from aa 15 to 20, aa 21 to 23, aa 44 to 46 or 47, aa 49 to 54, aa 58 to 61, aa 64 to 67, aa 78 to 81, aa 79 to 82, aa 189 to 192, aa 207 to 209, aa 214 to 217, aa 222 to 227, aa 236 to 241, aa 245 to 250, aa 267 to 269 or 270, and aa 294 to 296; a basic N-terminal domain characterized by aa 6 to 8; a hydrophobic domain characterized by aa 9 to 14 (FXVVVV, SEQ. ID. No. 6); a nucleotide binding domain characterized by aa 15 to 20 (GXGXXG, SEQ. ID. No. 7); an oxidoreductase domain characterized by aa 90 to 97 (AGKHVLVE, SEQ. ID. No. 8); a leucine zipper spanning aa 129 to 157 (LX6LX6KX6LX6L, SEQ. ID. No. 9); several kinase motifs, including aa 44 to 46 (SRR, SEQ. ID. No. 10), aa 147 to 149 (KGS, SEQ. ID. No. 11) and aa 162 to 164 (FGX, SEQ. ID. No. 12); a nuclear localization signal spanning aa 222 to 228 (GLKRNRY, SEQ. ID. No. 13); a myristylation site spanning aa 221 to 225 (PGLKR, SEQ. ID. No. 14); a zinc finger domain spanning aa 280 to 293 (HCX10CC, SEQ. ID. No. 15); and substrate binding domains including, without limitation, a protein kinase C (“PKC”) enhancing domain spanning aa 275 to 281 (KKRIXHC, SEQ. ID. No. 16) and a PKC inhibiting domain spanning aa 289 to 296 (QKXCXXXK, SEQ. ID. No. 17). By way of sequence comparison and, in consideration of conserved substitutions, hBVR of SEQ. ID. No. 3 and rBVR of SEQ. ID. No. 4 include similar functional domains. For example rBVR includes an identical hydrophobic domain, an identical nucleotide binding domain, an identical oxidoreductase domain, a conserved leucine zipper domain (with residue variations between L and K residues), identical or conserved kinase motifs, an identical nuclear localization signal, an identical myristylation site, a conserved zinc finger domain (with terminal C residue replaced by H), a conserved PKC enhancing domain, and a conserved PKC inhibiting domain.
  • DNA molecules encoding a BVR protein or polypeptide can also include a DNA molecule that hybridizes under stringent conditions to the DNA molecule having a nucleotide sequence of SEQ. ID. No. 2 or SEQ. ID. No. 5. An example of suitable stringency conditions is when hybridization is carried out at a temperature of about 37° C. using a hybridization medium that includes 0.9M sodium citrate (“SSC”) buffer, followed by washing with 0.2×SSC buffer at 37° C. Higher stringency can readily be attained by increasing the temperature for either hybridization or washing conditions or increasing the sodium concentration of the hybridization or wash medium. Nonspecific binding may also be controlled using any one of a number of known techniques such as, for example, blocking the membrane with protein-containing solutions, addition of heterologous RNA, DNA, and SDS to the hybridization buffer, and treatment with RNase. Wash conditions are typically performed at or below stringency. Exemplary high stringency conditions include carrying out hybridization at a temperature of about 42° C. to about 65° C. for up to about 20 hours in a hybridization medium containing 1M NaCl, 50 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.1% sodium dodecyl sulfate (SDS), 0.2% ficoll, 0.2% polyvinylpyrrolidone, 0.2% bovine serum albumin, and 50 μg/ml E. coli DNA, followed by washing carried out at between about 42° C. to about 65° C. in a 0.2×SSC buffer.
  • The BVR protein or polypeptide can also be a fragment of the above biliverdin reductase proteins or polypeptides or a variant thereof.
  • Fragments of BVR preferably contain one or more of the above-listed functional domains, and possess one or more of the activities of full length BVR. Suitable fragments can be produced by several means. Subclones of a gene encoding a known BVR can be produced using conventional molecular genetic manipulation for sub cloning gene fragments, such as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Laboratory, Cold Springs Harbor, N.Y. (1989), and Ausubel et al. (ed.), Current Protocols in Molecular Biology, John Wiley & Sons (New York, N.Y.) (1999 and preceding editions), each of which is hereby incorporated by reference in its entirety. The subclones then are expressed in vitro or in vivo in bacterial cells to yield a smaller protein or polypeptide that can be tested for a particular activity, e.g., converting biliverdin to bilirubin, modifying cell structure, etc., as discussed infra. See also Huang et al., J. Biol. Chem. 264:7844-7849 (1989), which is hereby incorporated by reference in its entirety.
  • In another approach, based on knowledge of the primary structure of the protein, fragments of a BVR gene may be synthesized using the PCR technique together with specific sets of primers chosen to represent particular portions of the protein. Erlich et al., Science 252:1643-51 (1991), which is hereby incorporated by reference in its entirety. These can then be cloned into an appropriate vector for expression of a truncated protein or polypeptide from bacterial cells as described above. For example, oligomers of at least about 15 to 20 nt in length can be selected from the nucleic acid molecules of SEQ. ID. No. 2 and SEQ ID. No. 5 for use as primers.
  • In addition, chemical synthesis can also be employed using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, J. Am. Chem. Assoc. 85:2149-2154 (1964), which is hereby incorporated by reference in its entirety) or synthesis in homogenous solution (Houbenweyl, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15, I and II, Thieme, Stuttgart (1987), which is hereby incorporated by reference in its entirety).
  • Variants of suitable BVR proteins or polypeptides can also be expressed. Variants may be made by, for example, the deletion, addition, or alteration of amino acids that have either (i) minimal influence on certain properties, secondary structure, and hydropathic nature of the polypeptide or (ii) substantial effect on one or more properties of BVR. Variants of BVR can also be fragments of BVR which include one or more deletion, addition, or alteration of amino acids of the type described above. The BVR variant preferably contains a deletion, addition, or alteration of amino acids within one of the above-listed functional domains. The substituted or additional amino acids can be either L-amino acids, D-amino acids, or modified amino acids, preferably L-amino acids. Whether a substitution, addition, or deletion results in modification of BVR variant activity may depend, at least in part, on whether the altered amino acid is conserved. Conserved amino acids can be grouped either by molecular weight or charge and/or polarity of R groups, acidity, basicity, and presence of phenyl groups, as is known in the art.
  • A number of BVR variants have been described in co-pending U.S. patent application Ser. No. 09/606,129 to Maines, filed Jun. 28, 2000, which is hereby incorporated by reference in its entirety.
  • Variants may also include, for example, a polypeptide conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification, identification, or therapeutic use (i.e., delivery) of the polypeptide.
  • The BVR protein or polypeptide can be recombinantly produced, isolated, and then purified, if necessary. When recombinantly produced, the biliverdin reductase protein or polypeptide is expressed in a recombinant host cell, typically, although not exclusively, a prokaryote.
  • When a prokaryotic host cell is selected for subsequent transformation, the promoter region used to construct the recombinant DNA molecule (i.e., transgene) should be appropriate for the particular host. The DNA sequences of eukaryotic promoters, as described infra for expression in eukaryotic host cells, differ from those of prokaryotic promoters. Eukaryotic promoters and accompanying genetic signals may not be recognized in or may not function in a prokaryotic system, and, further, prokaryotic promoters are not recognized and do not function in eukaryotic cells.
  • Similarly, translation of mRNA in prokaryotes depends upon the presence of the proper prokaryotic signals which differ from those of eukaryotes. Efficient translation of mRNA in prokaryotes requires a ribosome binding site called the Shine-Dalgarno (“SD”) sequence on the mRNA. This sequence is a short nucleotide sequence of mRNA that is located before the start codon, usually AUG, which encodes the amino-terminal methionine of the protein. The SD sequences are complementary to the 3′-end of the 16S rRNA (ribosomal RNA) and probably promote binding of mRNA to ribosomes by duplexing with the rRNA to allow correct positioning of the ribosome. For a review on maximizing gene expression, see Roberts and Lauer, Methods in Enzymology, 68:473 (1979), which is hereby incorporated by reference in its entirety.
  • Promoters vary in their “strength” (i.e., their ability to promote transcription). For the purposes of expressing a cloned gene, it is desirable to use strong promoters in order to obtain a high level of transcription and, hence, expression of the gene. Depending upon the host cell system utilized, any one of a number of suitable promoters may be used. For instance, when cloning in E. coli, its bacteriophages, or plasmids, promoters such as the T7 phage promoter, lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, the PR and PL promoters of coliphage lambda and others, including but not limited, to lacUV5, ompF, bla, lpp, and the like, may be used to direct high levels of transcription of adjacent DNA segments. Additionally, a hybrid trp-lacUV5 (tac) promoter or other E. coli promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted gene.
  • Bacterial host cell strains and expression vectors may be chosen which inhibit the action of the promoter unless specifically induced. In certain operons, the addition of specific inducers is necessary for efficient transcription of the inserted DNA. For example, the lac operon is induced by the addition of lactose or IPTG (isopropylthio-beta-D-galactoside). A variety of other operons, such as trp, pro, etc., are under different controls.
  • Specific initiation signals are also required for efficient gene transcription and translation in prokaryotic cells. These transcription and translation initiation signals may vary in “strength” as measured by the quantity of gene specific messenger RNA and protein synthesized, respectively. The DNA expression vector, which contains a promoter, may also contain any combination of various “strong” transcription and/or translation initiation signals. For instance, efficient translation in E. coli requires a Shine-Dalgarno (“SD”) sequence about 7-9 bases 5′ to the initiation codon (“ATG”) to provide a ribosome binding site. Thus, any SD-ATG combination that can be utilized by host cell ribosomes may be employed. Such combinations include, but are not limited to, the SD-ATG combination from the cro gene or the N gene of coliphage lambda, or from the E. coli tryptophan E, D, C, B or A genes. Additionally, any SD-ATG combination produced by recombinant DNA or other techniques involving incorporation of synthetic nucleotides may be used.
  • Mammalian cells can also be used to recombinantly produce BVR or fragments or variants thereof.
  • Suitable mammalian host cells include, without limitation: COS (e.g., ATCC No. CRL 1650 or 1651), BHK (e.g., ATCC No. CRL 6281), CHO (ATCC No. CCL 61), HeLa (e.g., ATCC No. CCL 2), 293 (ATCC No. 1573), CHOP, and NS-1 cells. Suitable expression vectors for directing expression in mammalian cells generally include a promoter, as well as other transcription and translation control sequences known in the art. Common promoters include, without limitation, SV40, MMTV, metallothionein-1, adenovirus Ela, CMV, immediate early, immunoglobulin heavy chain promoter and enhancer, and RSV-LTR.
  • Regardless of the selection of host cell, once the DNA molecule coding for a biliverdin reductase protein or polypeptide, or fragment or variant thereof, has been ligated to its appropriate regulatory regions using well known molecular cloning techniques, it can then be introduced into a suitable vector or otherwise introduced directly into a host cell using transformation protocols well known in the art (Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Press, NY (1989), which is hereby incorporated by reference in its entirety).
  • The recombinant molecule can be introduced into host cells via transformation, particularly transduction, conjugation, mobilization, or electroporation. Suitable host cells include, but are not limited to, bacteria, virus, yeast, mammalian cells, insect, plant, and the like. The host cells, when grown in an appropriate medium, are capable of expressing the biliverdin reductase, or fragment or variant thereof, which can then be isolated therefrom and, if necessary, purified. The BVR, or fragment or variant thereof, is preferably produced in purified form (preferably at least about 60%, more preferably 80%, pure) by conventional techniques.
  • For therapeutic purposes, the treated cell is preferably in vivo and the protein or polypeptide or RNA molecule is delivered into the cell in a manner which affords the protein or polypeptide or RNA molecule to be active within the cell. A number of known delivery techniques can be utilized for the delivery, into cells, of either proteins or polypeptides or RNA, or DNA molecules encoding them.
  • Regardless of the particular method of the present invention which is practiced, when it is desirable to contact a cell (i.e., to be treated) with a protein or polypeptide or RNA molecule, it is preferred that the contacting be carried out by delivery of the protein or polypeptide or RNA molecule into the cell.
  • One approach for delivering protein or polypeptides or RNA molecules into cells involves the use of liposomes. Basically, this involves providing a liposome which includes that protein or polypeptide or RNA to be delivered, and then contacting the target cell with the liposome under conditions effective for delivery of the protein or polypeptide or RNA into the cell.
  • Liposomes are vesicles comprised of one or more concentrically ordered lipid bilayers which encapsulate an aqueous phase. They are normally not leaky, but can become leaky if a hole or pore occurs in the membrane, if the membrane is dissolved or degrades, or if the membrane temperature is increased to the phase transition temperature. Current methods of drug delivery via liposomes require that the liposome carrier ultimately become permeable and release the encapsulated drug at the target site. This can be accomplished, for example, in a passive manner wherein the liposome bilayer degrades over time through the action of various agents in the body. Every liposome composition will have a characteristic half-life in the circulation or at other sites in the body and, thus, by controlling the half-life of the liposome composition, the rate at which the bilayer degrades can be somewhat regulated.
  • In contrast to passive drug release, active drug release involves using an agent to induce a permeability change in the liposome vesicle. Liposome membranes can be constructed so that they become destabilized when the environment becomes acidic near the liposome membrane (see, e.g., Proc. Natl. Acad. Sci. USA 84:7851 (1987); Biochemistry 28:908 (1989), which is hereby incorporated by reference in its entirety). When liposomes are endocytosed by a target cell, for example, they can be routed to acidic endosomes which will destabilize the liposome and result in drug release.
  • Alternatively, the liposome membrane can be chemically modified such that an enzyme is placed as a coating on the membrane which slowly destabilizes the liposome. Since control of drug release depends on the concentration of enzyme initially placed in the membrane, there is no real effective way to modulate or alter drug release to achieve “on demand” drug delivery. The same problem exists for pH-sensitive liposomes in that as soon as the liposome vesicle comes into contact with a target cell, it will be engulfed and a drop in pH will lead to drug release.
  • This liposome delivery system can also be made to accumulate at a target organ, tissue, or cell via active targeting (e.g., by incorporating an antibody or hormone on the surface of the liposomal vehicle). This can be achieved according to known methods.
  • Different types of liposomes can be prepared according to Bangham et al., J. Mol. Biol. 13:238-252 (1965); U.S. Pat. No. 5,653,996 to Hsu et al.; U.S. Pat. No. 5,643,599 to Lee et al.; U.S. Pat. No. 5,885,613 to Holland et al.; U.S. Pat. No. 5,631,237 to Dzau et al.; and U.S. Pat. No. 5,059,421 to Loughrey et al., each of which is hereby incorporated by reference in its entirety.
  • An alternative approach for delivery of proteins or polypeptides involves the conjugation of the desired protein or polypeptide to a polymer that is stabilized to avoid enzymatic degradation of the conjugated protein or polypeptide. Conjugated proteins or polypeptides of this type are described in U.S. Pat. No. 5,681,811 to Ekwuribe, which is hereby incorporated by reference in its entirety.
  • Yet another approach for delivery of proteins or polypeptides involves preparation of chimeric proteins according to U.S. Pat. No. 5,817,789 to Heartlein et al., which is hereby incorporated by reference in its entirety. The chimeric protein can include a ligand domain and, e.g., BVR or a fragment or variant thereof. The ligand domain is specific for receptors located on a target cell. Thus, when the chimeric protein is delivered intravenously or otherwise introduced into blood or lymph, the chimeric protein will adsorb to the targeted cell, and the targeted cell will internalize the chimeric protein.
  • When it is desirable to achieve heterologous expression of a desirable protein or polypeptide or RNA molecule in a target cell, DNA molecules encoding the desired protein or polypeptide or RNA can be delivered into the cell. Basically, this includes providing a nucleic acid molecule encoding the protein or polypeptide and then introducing the nucleic acid molecule into the cell under conditions effective to express the protein or polypeptide or RNA in the cell. Preferably, this is achieved by inserting the nucleic acid molecule into an expression vector before it is introduced into the cell.
  • When transforming mammalian cells for heterologous expression of a protein or polypeptide, an adenovirus vector can be employed. Adenovirus gene delivery vehicles can be readily prepared and utilized given the disclosure provided in Berkner, Biotechniques 6:616-627 (1988) and Rosenfeld et al., Science 252:431-434 (1991), WO 93/07283, WO 93/06223, and WO 93/07282, each of which is hereby incorporated by reference in its entirety. Adeno-associated viral gene delivery vehicles can be constructed and used to deliver a gene to cells. The use of adeno-associated viral gene delivery vehicles in vitro is described in Chatterjee et al., Science 258:1485-1488 (1992); Walsh et al., Proc. Nat'l. Acad. Sci. 89:7257-7261 (1992); Walsh et al., J. Clin. Invest. 94:1440-1448 (1994); Flotte et al., J. Biol. Chem. 268:3781-3790 (1993); Ponnazhagan et al., J. Exp. Med. 179:733-738 (1994); Miller et al., Proc. Nat'l Acad. Sci. 91:10183-10187 (1994); Einerhand et al., Gene Ther. 2:336-343 (1995); Luo et al., Exp. Hematol. 23:1261-1267 (1995); and Zhou et al., Gene Ther. 3:223-229 (1996), each of which is hereby incorporated by reference in its entirety. In vivo use of these vehicles is described in Flotte et al., Proc. Nat'l Acad. Sci. 90:10613-10617 (1993); and Kaplitt et al., Nature Genet. 8:148-153 (1994), each of which is hereby incorporated by reference in its entirety. Additional types of adenovirus vectors are described in U.S. Pat. No. 6,057,155 to Wickham et al.; U.S. Pat. No. 6,033,908 to Bout et al.; U.S. Pat. No. 6,001,557 to Wilson et al.; U.S. Pat. No. 5,994,132 to Chamberlain et al.; U.S. Pat. No. 5,981,225 to Kochanek et al.; and U.S. Pat. No. 5,885,808 to Spooner et al.; and U.S. Pat. No. 5,871,727 to Curiel, each of which is hereby incorporated by reference in its entirety.
  • Retroviral vectors which have been modified to form infective transformation systems can also be used to deliver nucleic acid encoding a desired protein or polypeptide or RNA product into a target cell. One such type of retroviral vector is disclosed in U.S. Pat. No. 5,849,586 to Kriegler et al., which is hereby incorporated by reference in its entirety.
  • Regardless of the type of infective transformation system employed, it can be targeted for delivery of the nucleic acid to a specific cell type. For example, for delivery of the nucleic acid into specific cells, a high titer of the infective transformation system can be injected directly within the desired site so as to enhance the likelihood of cell infection within the desired site. The infected cells will then express the desired protein product, in this case BVR, or fragments or variants thereof, to modify the structure of those cells which have been infected.
  • Whether the proteins or polypeptides or nucleic acids are administered alone or in combination with pharmaceutically or physiologically acceptable carriers, excipients, or stabilizers, or in solid or liquid form such as, tablets, capsules, powders, solutions, suspensions, or emulsions, they can be administered orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes, such as, that of the nose, throat, and bronchial tubes. For most therapeutic purposes, the proteins or polypeptides or nucleic acids can be administered intravenously.
  • For injectable dosages, solutions or suspensions of these materials can be prepared in a physiologically acceptable diluent with a pharmaceutical carrier. Such carriers include sterile liquids, such as water and oils, with or without the addition of a surfactant and other pharmaceutically and physiologically acceptable carrier, including adjuvants, excipients or stabilizers. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solution, and glycols, such as propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions.
  • For use as aerosols, the proteins or polypeptides or nucleic acids in solution or suspension may be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants. The materials of the present invention also may be administered in a non-pressurized form such as in a nebulizer or atomizer.
  • Both the biliverdin reductase and fragments or variants thereof can be delivered to the target cells (i.e., at or around the site where cell modification is desired) using the above-described methods for delivering such therapeutic products. In delivering the therapeutic products to nerve cells in the brain, consideration should be provided to negotiation of the blood-brain barrier. The blood-brain barrier typically prevents many compounds in the blood stream from entering the tissues and fluids of the brain. Nature provides this mechanism to insure a toxin-free environment for neurologic function. However, it also prevents delivery to the brain of compounds, in this case neuroprotective compounds that can inhibit nerve cell death following an ischemic event.
  • One approach for negotiating the blood-brain barrier is described in U.S. Pat. No. 5,752,515 to Jolesz et al., which is hereby incorporated by reference in its entirety. Basically, the blood-brain barrier is temporarily “opened” by targeting a selected location in the brain and applying ultrasound to induce, in the central nervous system (CNS) tissues and/or fluids at that location, a change detectable by imaging. A protein or polypeptide or RNA molecule of the present invention can be delivered to the targeted region of the brain while the blood-brain barrier remains “open,” allowing targeted neuronal cells to uptake the delivered protein or polypeptide or RNA. At least a portion of the brain in the vicinity of the selected location can be imaged, e.g., via magnetic resonance imaging, to confirm the location of the change. Alternative approaches for negotiating the blood-brain barrier include chimeric peptides and modified liposome structures which contain a PEG moiety (reviewed in Pardridge, J. Neurochem. 70:1781-1792 (1998), which is hereby incorporated by reference in its entirety), as well as osmotic opening (i.e., with bradykinin, mannitol, RPM7, etc.) and direct intracerebral infusion (Kroll et al., Neurosurgery 42(5):1083-1100 (1998), which is hereby incorporated by reference in its entirety).
  • Analysis of the promoter region associated with the nucleic acid encoding rBVR indicates the presence of recognition sites for several regulating proteins, including INF-1, an enhancer of cytokine and virus-induced transcriptional activation, and AP-1, the proto-oncogene binding site (McCoubrey et al., “The Structure, Organization and Differential Expression of the Rat Gene Encoding Biliverdin Reductase,” Gene 160:235-240 (1995), which is hereby incorporated by reference in its entirety. Also, two elements known to be involved in embryonic gene expression, P3A and engrailed, are present in the promoter region of this gene. These criteria are consistent with the function of BVR in a regulatory capacity in the cell.
  • As discussed in greater detail in the Examples, it has been discovered that transformation of mammalian cells with biliverdin reductase is effective in modifying the structure of the transformed mammalian cells. It is believed that the increase in biliverdin reductase in the cell is responsible for having modified cell structure. Therefore, one aspect of the present invention relates to a method of modifying cell structure which includes: increasing the intracellular concentration of biliverdin reductase, or a fragment or variant thereof, in a mammalian cell under conditions effective to modify the structure of the mammalian cell.
  • Where the cellular concentration of biliverdin reductase is increased, it should be appreciate that some basal level of biliverdin reductase may exist in the cell which has been targeted. Thus, the increase in biliverdin reductase intracellular concentration is simply the result of causing more biliverdin reductase to be expressed (e.g., inducing or transforming) or introducing additional biliverdin reductase from an external source (i.e., administration).
  • In contrast, because biliverdin reductase fragments and variants are not normally expressed in mammalian cells, any increase in biliverdin reductase fragments or variants is the result of their heterologous expression (i.e., transforming) or introducing biliverdin reductase fragments or variants from an external source (i.e., administering).
  • Regardless of whether it is biliverdin reductase or its fragments or variants whose cellular concentration is increased in the mammalian cell to be modified, the increase in concentration can be achieved by introducing the BVR or BVR fragments or variants into the cell. Typically, this is done by contacting the mammalian cell (to be modified) with a delivery vehicle which includes biliverdin reductase or a fragment or variant thereof. The delivery vehicle can be any delivery vehicle of the type described above for protein delivery.
  • Likewise, such increase in cellular concentration can be achieved by heterologous expression by the mammalian cell (to be modified). Such heterologous expression is typically the result of transforming the mammalian cell with a nucleic acid encoding biliverdin reductase or a fragment or variant thereof under conditions effective for expression of the biliverdin reductase or the fragment or variant thereof in the mammalian cell. The transformation can be achieved using any nucleic acid delivery system of the type described above. (e.g., infective transformation).
  • The mammalian cells which can be treated include, without limitation, stem cells (both omnipotent and pluripotent stem cells), neuronal or glial cells, vascular smooth muscle cells, skeletal muscle cells, epithelial cells, and nucleated blood cells (e.g., macrophages and other blood cells). The mammalian cells whose structure is modified can be either in vitro or in vivo when their structure is modified.
  • Exemplary aspects of the mammalian cell structure which can be modified in accordance with the present invention include, without limitation, enhanced cell size (i.e., forming giant cells), actin microspike formation, polar cell morphology (i.e., with protracted filopodia extensions), and a combination thereof.
  • Without being bound by theory, it is believed that the modified cell structure is the result of biliverdin reductase interaction with proteins and kinases that govern cell cycling and with polypeptide growth factors.
  • In view of the modified cell structure, it is further contemplated that the present invention can be utilized to perform organogenesis, tissue remodeling, wound healing, angiogenesis, or combinations thereof. Tissue remodeling, of course, encompasses both wound healing and angiogenesis.
  • Thus, a further aspect of the present invention relates to a method of performing in vivo tissue remodeling in a mammal. This aspect of the invention includes: delivering biliverdin reductase, or fragments or variants thereof, to one or more cells present at a site of tissue remodeling in a mammal, wherein the delivering (of BVR or its fragments or variants) increases the intracellular concentration of biliverdin reductase, or fragments or variants thereof, under conditions effective to modify the structure of the one or more cells at the site of tissue remodeling, thereby remodeling the tissue containing the one or more cells.
  • Tissues which can be remodeled in vivo include, without limitation, epithelial tissues, nerve tissues, muscular tissues (both smooth muscle and skeletal muscle tissues), or connective tissue. More specifically, angiogenesis can implicate remodeling of vascular tissue and modifying the structure of vascular smooth muscle, bladder, and urinary tract cells. Likewise, wound healing can implicate remodeling of epithelial tissues, nerve tissues, muscular tissues (both smooth muscle and skeletal muscle tissues), or connective tissues via modifying the structures of epithelial cells, nerve or glial cells, vascular and skeletal muscle cells, etc.
  • As a result of such tissue remodeling, where multiple tissues are remodeled, it also contemplated to utilize the present invention according to a method of repairing a damaged organ or organ system by performing the method of in vivo tissue remodeling in accordance with the present invention, where the site of tissue remodeling is within the damaged organ or organ system. Exemplary organ or organ systems which can be subject to repair include, without limitation, skin, liver, nervous system (e.g., both sensory neurons and motor neurons), cardiovascular system, and urogenital tract.
  • With respect specifically to wound healing, it should be appreciated that the primary goal in the treatment of wounds is to achieve wound closure. Open cutaneous wounds represent one major category of wounds and include burn wounds, neuropathic ulcers, pressure sores, venous stasis ulcers, and diabetic ulcers. Open cutaneous wounds routinely heal by a process which comprises six major components: i) inflammation, ii) fibroblast proliferation, iii) blood vessel proliferation, iv) connective tissue synthesis v) epithelialization, and vi) wound contraction. Wound healing is impaired when these components, either individually or as a whole, do not function properly. Numerous factors can affect wound healing, including malnutrition, infection, pharmacological agents (e.g., actinomycin and steroids), diabetes, and advanced age (see Hunt and Goodson, 1988). In general, agents which promote a more rapid influx of fibroblasts, endothelial and epithelial cells into wounds should increase the rate at which wounds heal. By virtue of increasing the intracellular concentration of biliverdin reductase, it becomes possible to induce an increase in cell size, the formation of actin microspikes, and morphological changes in cell polarity, i.e., formation of filopodia extensions. These aspects suggest that the affected cells can be made more readily able to influx into damage sites in need of repair.
  • The use of BVR for wound healing can also be carried out in combination with a medicament selected from the group consisting of an antibacterial agent, an antiviral agent, an antifungal agent, an antiparasitic agent, an anti-inflammatory agent, an analgesic agent, an antipruritic agent, or a combination thereof For cutaneous wound healing, a preferred mode of administration is by the topical route.
    • EXAMPLES
  • The following examples are intended to illustrate, but by no means are intended to limit, the scope of the present invention as set forth in the appended claims.
    • Example 1 In Vitro Transformation of HeLa Cells with Biliverdin Reductase for Modifying Cellular Structure
  • HeLa cells were transfected in vitro with biliverdin reductase encoding DNA. A HeLa cell suspension having a density of about 12×104/ml was introduced to a 12-well plate using 0.2 ml of the cell suspension per well (i.e., about 2.4×104 cells per well). The following protocol was employed for transfection:
  • Cells were washed with DMEM (serum). Thereafter, the following solution was added: 2 μl of DNA (541 0.5 μg/μl), 50 μl of DMEM(−), and 2 μl of lipofectimine. After 4-5 h, 0.5 ml of DMEM (20% serum) was added followed by 30 h incubation (37° C.).
  • On the following day cells were immunostained using the following protocol. HeLa cells were washed once for 5 min in PBS (0.1% PB, 0.9% NaCl), followed by treatment with 4% PFA (on ice). 10 min later, cells were washed 3 times for 5 min each time in PBS. Cells were blocked by treatment with PBS (950 μl)+50 μl horse serum (5% HS PBS) for 1 h at room temperature. Cells were treated with a solution of 3% HS-0.25% Triton-PBS at 4° C. overnight, thereafter cells were treated with 1:1000 dilution of BVR antibody.
  • For antibody staining, cells were washed 3 times for 5 min each time in PBS—0.25% Triton×100 and treated with second antibody solution consisting of: horse serum, 15 μl/ml and antimouse-IgG, 5 μl/ml. After 3 times washing with PBS for 5 min each time, cells were visualized using ABC solution (Vector Labs) and stained for 30 min.
  • Non specific staining was removed using 3% of H2O2 . Cells were then washed with dd H2O and dehydrated in 95%-100% ethanol, xylene 5 min. Slides were mounted with ½ permount+½ xylene
  • Control and transformed HeLa cells were visualized by immunostaining using antibody to BVR. As shown in FIGS. 1-6, the transformed HeLa cells displayed larger cell size relative to control cells, formation of actin microspikes, and polar cell morphology with filopodia extensions.
  • The above results indicate that BVR is a regulator of cell proliferation and cell differentiation. Following transformation to induce an increase in BVR expression, transfected cells were transformed into giant cells several times the size of normal cells. Moreover, the transfected cells displayed formation of actin microspikes. Such actin microspikes are known to act as sensory devices by which cells explore their environment. Also, BVR transfected cells exhibited polar cell morphology, as characterized by protracted filopodia extensions that resemble that of neuronal axon and dendritic extensions, a phenotype which is not displayed by Cdc42 transfected cells (Adams and Schwarz, “Stimulation of Fasein Spikes by Thrombospondin-1 is Mediated by GTPases Rac and Cdc42,” J. Cell Biol. 150:807-822 (2000), which is hereby incorporated by reference in its entirety). These properties are displayed by certain cyclin-dependent kinases. Specifically, Cdc42 kinase stimulates spike formation (Kozma et al., “The Ras-related protein Cdc42Hs and Bradykinin Promote Formation of Peripheral Actin Microspikes and Filopodia in Swiss 3T3 Fibroblasts,” Mol. Cell Biol. 15:1942-1952 (1995); Nobes and Hall, “Rho, Rac, and Cdc42 GTPases Regulate the Assembly of Multimolecular Focal Complexes Associated with Actin Stress Fibers, Lamellipodia, and Filopodia,” Cell 81:53-62 (1995); Adams and Schwarz, “Stimulation of Fasein Spikes by Thrombospondin-1 is Mediated by GTPases Rac and Cdc42,” J. Cell Biol. 150:807-822 (2000), each of which is hereby incorporated by reference in its entirety) and D type cyclins, e.g., cyclin D2, deregulate cell size and cause cell mass increase (Kershoff and Ziff, “Cyclin D2 Ha-Ras Transformed Rat Embryo Fibroblasts Exhibit Novel Deregulation of Cell Size Control and Early S Phase Arrest in Low Serum,” EMBO J. 14:1892-1903 (1995), which is hereby incorporated by reference in its entirety). These proteins require cooperation of signal transduction kinase activity, e.g., GTPases Rac/Ha-Ras (Adams and Schwarz, “Stimulation of Fasein Spikes by Thrombospondin-1 is Mediated by GTPases Rac and Cdc42,” J. Cell Biol. 150:807-822 (2000); Kershoff and Ziff, “Cyclin D2 and Ha-Ras Transformed Rat Embryo Fibroblasts Exhibit Novel Deregulation of Cell Size Control and Early S Phase Arrest in Low Serum,” EMBO J. 14:1892-1903 (1995), each of which is hereby incorporated by reference in its entirety). BVR, as noted above, is a protein kinase and has both cell proliferating and cell differentiation activities. Furthermore, BVR can unexpectedly control the cell size under normal conditions, whereas cyclin D2 and Ha-Ras transformed cells only display giant size in low serum conditions. The morphology of the above-described transformed cells is also consistent with the use of BVR expression for promoting axonal growth in the case of nerve damage.
  • In a number of amino acid sequences, X is used to depict a residue which can be any naturally occurring amino acid, unless otherwise indicated.
  • Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention which is defined by the following claims.

Claims (13)

1. A method of in vivo tissue remodeling in a mammal comprising:
delivering biliverdin reductase, or fragments or variants thereof, to one or more cells present at a site of tissue remodeling in a mammal, wherein said delivering increases the intracellular concentration of biliverdin reductase, or fragments or variants thereof, under conditions effective to modify the structure of the one or more cells at the site of tissue remodeling, thereby remodeling the tissue containing the one or more cells.
2. The method according to claim 1, wherein the tissue is epithelial tissue, nerve tissue, muscular tissue, or connective tissue.
3. The method according to claim 1 wherein the one or more cells is a stem cell, a neuronal or glial cell, a vascular smooth muscle cell, a skeletal muscle cell, an epithelial cell, a nucleated blood cell, or a combination thereof.
4. The method according claim 1 wherein said delivering comprises:
introducing biliverdin reductase into the one or more cells.
5. The method according claim 4 wherein said introducing comprises:
contacting each of the one or more cells with a delivery vehicle comprising biliverdin reductase.
6. The method according to claim 5 wherein the delivery vehicle comprises a fusion protein comprising biliverdin reductase and a ligand domain recognized by a receptor of the one or more cells.
7. The method according to claim 5 wherein the delivery vehicle comprises a liposome containing biliverdin reductase.
8. The method according to claim 5 wherein the delivery vehicle comprises an enzymatically stable conjugate comprising a polymer and biliverdin reductase conjugated to the polymer.
9. The method according to claim 1 wherein said delivering comprises:
transforming each of the one or more cells with a nucleic acid encoding biliverdin reductase under conditions effective for expression of the biliverdin reductase in the one or more cells.
10. The method according to claim 9 wherein said transforming comprises:
transfecting each of the one or more cells with an infective transformation vector comprising the nucleic acid encoding biliverdin reductase.
11. The method according to claim 10 wherein the infective transformation vector is an adenovirus vector or a retrovirus vector.
12. A method of repairing a damaged organ or organ system by performing said method of in vivo tissue remodeling according to claim 1, where the site of tissue remodeling is within the damaged organ or organ system.
13. The method according to claim 12, wherein the organ or organ system is skin, liver, nervous system, cardiovascular system, or urogenital tract.
US11/205,562 2001-01-12 2005-08-17 Methods of modifying cell structure and remodeling tissue Abandoned US20050287130A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/205,562 US20050287130A1 (en) 2001-01-12 2005-08-17 Methods of modifying cell structure and remodeling tissue

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26150001P 2001-01-12 2001-01-12
US10/045,545 US6969610B2 (en) 2001-01-12 2002-01-14 Methods of modifying cell structure and remodeling tissue
US11/205,562 US20050287130A1 (en) 2001-01-12 2005-08-17 Methods of modifying cell structure and remodeling tissue

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/045,545 Division US6969610B2 (en) 2001-01-12 2002-01-14 Methods of modifying cell structure and remodeling tissue

Publications (1)

Publication Number Publication Date
US20050287130A1 true US20050287130A1 (en) 2005-12-29

Family

ID=26722902

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/045,545 Expired - Fee Related US6969610B2 (en) 2001-01-12 2002-01-14 Methods of modifying cell structure and remodeling tissue
US11/205,562 Abandoned US20050287130A1 (en) 2001-01-12 2005-08-17 Methods of modifying cell structure and remodeling tissue

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/045,545 Expired - Fee Related US6969610B2 (en) 2001-01-12 2002-01-14 Methods of modifying cell structure and remodeling tissue

Country Status (1)

Country Link
US (2) US6969610B2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033277A2 (en) * 2003-09-29 2005-04-14 University Of Rochester Methods of modulating cell cycle and cell signaling pathways using biliverdin reductase
US7504243B2 (en) * 2004-03-19 2009-03-17 The United States Of America As Represented By The Department Of Health And Human Services Methods for the production of biliverdin
WO2006089270A2 (en) * 2005-02-18 2006-08-24 University Of Rochester Methods of modifying insulin signaling using biliverdin reductase
US20100303790A1 (en) * 2009-05-06 2010-12-02 University Of Rochester Use of biliverdin reductase (bvr) and bvr peptide fragments to treat coronary disorders
US8455222B2 (en) 2009-11-04 2013-06-04 Utah State University Biliverdin from a non-animal source
US9078913B2 (en) * 2009-11-06 2015-07-14 University Of Rochester Use of human Biliverdin reductase and fragments thereof protein kinase C-δ and ERK related conditions
WO2014043647A1 (en) 2012-09-14 2014-03-20 Utah State University Therapeutic compositions and associated methods

Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003376A (en) * 1975-08-25 1977-01-18 Bio-Dynamics, Inc. Apparatus for straightening the spinal column
US4848328A (en) * 1986-05-20 1989-07-18 Laboureau Jacques P Agraffe for osteosynthesis
US5034011A (en) * 1990-08-09 1991-07-23 Advanced Spine Fixation Systems Incorporated Segmental instrumentation of the posterior spine
US5053038A (en) * 1989-08-17 1991-10-01 Tenstaple, Inc. Compression bone staple
US5290289A (en) * 1990-05-22 1994-03-01 Sanders Albert E Nitinol spinal instrumentation and method for surgically treating scoliosis
US5480401A (en) * 1993-02-17 1996-01-02 Psi Extra-discal inter-vertebral prosthesis for controlling the variations of the inter-vertebral distance by means of a double damper
US5562737A (en) * 1993-11-18 1996-10-08 Henry Graf Extra-discal intervertebral prosthesis
US5593408A (en) * 1994-11-30 1997-01-14 Sofamor S.N.C Vertebral instrumentation rod
US5700292A (en) * 1992-11-09 1997-12-23 Hospital For Joint Diseases Spinal stabilization system and method
US5728098A (en) * 1996-11-07 1998-03-17 Sdgi Holdings, Inc. Multi-angle bone screw assembly using shape-memory technology
US5797911A (en) * 1996-09-24 1998-08-25 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US5853414A (en) * 1991-05-09 1998-12-29 Groiso; Jorge A. Elastic clip for osteosynthesis
US5879350A (en) * 1996-09-24 1999-03-09 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US5885286A (en) * 1996-09-24 1999-03-23 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US5891145A (en) * 1997-07-14 1999-04-06 Sdgi Holdings, Inc. Multi-axial screw
US6127597A (en) * 1997-03-07 2000-10-03 Discotech N.V. Systems for percutaneous bone and spinal stabilization, fixation and repair
US6254602B1 (en) * 1999-05-28 2001-07-03 Sdgi Holdings, Inc. Advanced coupling device using shape-memory technology
US6273888B1 (en) * 1999-05-28 2001-08-14 Sdgi Holdings, Inc. Device and method for selectively preventing the locking of a shape-memory alloy coupling system
US6280442B1 (en) * 1999-09-01 2001-08-28 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US6287308B1 (en) * 1997-07-14 2001-09-11 Sdgi Holdings, Inc. Methods and apparatus for fusionless treatment of spinal deformities
US6299613B1 (en) * 1999-04-23 2001-10-09 Sdgi Holdings, Inc. Method for the correction of spinal deformities through vertebral body tethering without fusion
US6325805B1 (en) * 1999-04-23 2001-12-04 Sdgi Holdings, Inc. Shape memory alloy staple
US6396643B1 (en) * 1999-04-06 2002-05-28 Olympus Optical Co., Ltd. Zoom lens
US20020151895A1 (en) * 2001-02-16 2002-10-17 Soboleski Donald A. Method and device for treating scoliosis
US6471703B1 (en) * 1999-04-21 2002-10-29 Sdgi Holdings, Inc. Variable angle connection assembly for a spinal implant system
US6485491B1 (en) * 2000-09-15 2002-11-26 Sdgi Holdings, Inc. Posterior fixation system
US20030023241A1 (en) * 1999-04-23 2003-01-30 Drewry Troy D. Adjustable spinal tether
US6530929B1 (en) * 1999-10-20 2003-03-11 Sdgi Holdings, Inc. Instruments for stabilization of bony structures
US20030088251A1 (en) * 2001-11-05 2003-05-08 Braun John T Devices and methods for the correction and treatment of spinal deformities
US20030153912A1 (en) * 2000-06-30 2003-08-14 Henry Graf Intervertebral connecting device
US6610091B1 (en) * 1999-10-22 2003-08-26 Archus Orthopedics Inc. Facet arthroplasty devices and methods
US20040034351A1 (en) * 2002-08-14 2004-02-19 Sherman Michael C. Techniques for spinal surgery and attaching constructs to vertebral elements
US6709434B1 (en) * 1998-07-30 2004-03-23 Sofamor S.N.C. Spinal osteosynthesis device
US20040102774A1 (en) * 2002-11-21 2004-05-27 Trieu Hai H. Systems and techniques for intravertebral spinal stabilization with expandable devices
US6746450B1 (en) * 1999-07-07 2004-06-08 Children's Hospital Medical Center Spinal correction system
US6755830B2 (en) * 2001-07-04 2004-06-29 Sofamor S.N.C. Connector for a spinal fixation member
US6835205B2 (en) * 2000-04-04 2004-12-28 Spinalabs, Llc Devices and methods for the treatment of spinal disorders
US6837904B2 (en) * 2001-07-16 2005-01-04 Spinecore, Inc. Method of surgically treating scoliosis
US20050021035A1 (en) * 2002-01-22 2005-01-27 Groiso Jorge Abel Bone staple and methods for correcting bone deficiencies by controllably suppressing and/or inducing the growth of the epiphyseal plate
US20050080420A1 (en) * 2003-08-20 2005-04-14 Farris Robert A. Multi-axial orthopedic device and system
US20050171539A1 (en) * 2004-01-30 2005-08-04 Braun John T. Orthopedic distraction implants and techniques
US20050216004A1 (en) * 2004-03-23 2005-09-29 Schwab Frank J Device and method for dynamic spinal fixation for correction of spinal deformities
US20050234451A1 (en) * 2004-04-16 2005-10-20 Markworth Aaron D Pedicle screw assembly
US6974478B2 (en) * 1999-10-22 2005-12-13 Archus Orthopedics, Inc. Prostheses, systems and methods for replacement of natural facet joints with artificial facet joint surfaces
US20050283157A1 (en) * 2004-06-17 2005-12-22 Coates Bradley J Multi-axial bone attachment assembly
US20060116677A1 (en) * 2004-12-01 2006-06-01 Burd Brian A Side-loading bone anchor
US7074239B1 (en) * 2001-04-25 2006-07-11 Cytori Therapeutics, Inc. Resorbable posterior spinal fusion system
US20060155279A1 (en) * 2004-10-28 2006-07-13 Axial Biotech, Inc. Apparatus and method for concave scoliosis expansion
US20060235392A1 (en) * 2004-08-27 2006-10-19 Hammer Michael A Multi-axial connection system

Patent Citations (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003376A (en) * 1975-08-25 1977-01-18 Bio-Dynamics, Inc. Apparatus for straightening the spinal column
US4848328A (en) * 1986-05-20 1989-07-18 Laboureau Jacques P Agraffe for osteosynthesis
US5053038A (en) * 1989-08-17 1991-10-01 Tenstaple, Inc. Compression bone staple
US5290289A (en) * 1990-05-22 1994-03-01 Sanders Albert E Nitinol spinal instrumentation and method for surgically treating scoliosis
US5034011A (en) * 1990-08-09 1991-07-23 Advanced Spine Fixation Systems Incorporated Segmental instrumentation of the posterior spine
US5853414A (en) * 1991-05-09 1998-12-29 Groiso; Jorge A. Elastic clip for osteosynthesis
US5700292A (en) * 1992-11-09 1997-12-23 Hospital For Joint Diseases Spinal stabilization system and method
US5480401A (en) * 1993-02-17 1996-01-02 Psi Extra-discal inter-vertebral prosthesis for controlling the variations of the inter-vertebral distance by means of a double damper
US5562737A (en) * 1993-11-18 1996-10-08 Henry Graf Extra-discal intervertebral prosthesis
US5593408A (en) * 1994-11-30 1997-01-14 Sofamor S.N.C Vertebral instrumentation rod
US5797911A (en) * 1996-09-24 1998-08-25 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US5879350A (en) * 1996-09-24 1999-03-09 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US5885286A (en) * 1996-09-24 1999-03-23 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US6053917A (en) * 1996-09-24 2000-04-25 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US6287311B1 (en) * 1996-11-07 2001-09-11 Sdgi Holdings, Inc. Multi-angle bone screw assembly using shape-memory technology
US5728098A (en) * 1996-11-07 1998-03-17 Sdgi Holdings, Inc. Multi-angle bone screw assembly using shape-memory technology
US5954725A (en) * 1996-11-07 1999-09-21 Sdgi Holdings, Inc. Multi-angle bone screw assembly using shape memory technology
US6132434A (en) * 1996-11-07 2000-10-17 Sdgi Holdings, Inc. Multi-angle bone screw assembly using shape-memory technology
US6454773B1 (en) * 1996-11-07 2002-09-24 Sdgi Holdings, Inc. Multi-angle bone screw assembly using shape-memory technology
US6127597A (en) * 1997-03-07 2000-10-03 Discotech N.V. Systems for percutaneous bone and spinal stabilization, fixation and repair
US5891145A (en) * 1997-07-14 1999-04-06 Sdgi Holdings, Inc. Multi-axial screw
US6287308B1 (en) * 1997-07-14 2001-09-11 Sdgi Holdings, Inc. Methods and apparatus for fusionless treatment of spinal deformities
US6623484B2 (en) * 1997-07-14 2003-09-23 Sdgi Holdings, Inc. Methods and apparatus for fusionless treatment of spinal deformities
US6709434B1 (en) * 1998-07-30 2004-03-23 Sofamor S.N.C. Spinal osteosynthesis device
US6396643B1 (en) * 1999-04-06 2002-05-28 Olympus Optical Co., Ltd. Zoom lens
US6471703B1 (en) * 1999-04-21 2002-10-29 Sdgi Holdings, Inc. Variable angle connection assembly for a spinal implant system
US6616669B2 (en) * 1999-04-23 2003-09-09 Sdgi Holdings, Inc. Method for the correction of spinal deformities through vertebral body tethering without fusion
US6299613B1 (en) * 1999-04-23 2001-10-09 Sdgi Holdings, Inc. Method for the correction of spinal deformities through vertebral body tethering without fusion
US6325805B1 (en) * 1999-04-23 2001-12-04 Sdgi Holdings, Inc. Shape memory alloy staple
US20030023241A1 (en) * 1999-04-23 2003-01-30 Drewry Troy D. Adjustable spinal tether
US6273888B1 (en) * 1999-05-28 2001-08-14 Sdgi Holdings, Inc. Device and method for selectively preventing the locking of a shape-memory alloy coupling system
US6254602B1 (en) * 1999-05-28 2001-07-03 Sdgi Holdings, Inc. Advanced coupling device using shape-memory technology
US6746450B1 (en) * 1999-07-07 2004-06-08 Children's Hospital Medical Center Spinal correction system
US20040116929A1 (en) * 1999-09-01 2004-06-17 Barker B. Thomas Multi-axial bone screw assembly
US6280442B1 (en) * 1999-09-01 2001-08-28 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US6660004B2 (en) * 1999-09-01 2003-12-09 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US6530929B1 (en) * 1999-10-20 2003-03-11 Sdgi Holdings, Inc. Instruments for stabilization of bony structures
US6974478B2 (en) * 1999-10-22 2005-12-13 Archus Orthopedics, Inc. Prostheses, systems and methods for replacement of natural facet joints with artificial facet joint surfaces
US20060100709A1 (en) * 1999-10-22 2006-05-11 Reiley Mark A Facet arthroplasty devices and methods
US6610091B1 (en) * 1999-10-22 2003-08-26 Archus Orthopedics Inc. Facet arthroplasty devices and methods
US6835205B2 (en) * 2000-04-04 2004-12-28 Spinalabs, Llc Devices and methods for the treatment of spinal disorders
US20030153912A1 (en) * 2000-06-30 2003-08-14 Henry Graf Intervertebral connecting device
US20030004512A1 (en) * 2000-09-15 2003-01-02 Farris Robert A. Posterior fixation system
US6485491B1 (en) * 2000-09-15 2002-11-26 Sdgi Holdings, Inc. Posterior fixation system
US20020151895A1 (en) * 2001-02-16 2002-10-17 Soboleski Donald A. Method and device for treating scoliosis
US7074239B1 (en) * 2001-04-25 2006-07-11 Cytori Therapeutics, Inc. Resorbable posterior spinal fusion system
US6755830B2 (en) * 2001-07-04 2004-06-29 Sofamor S.N.C. Connector for a spinal fixation member
US6837904B2 (en) * 2001-07-16 2005-01-04 Spinecore, Inc. Method of surgically treating scoliosis
US20030088251A1 (en) * 2001-11-05 2003-05-08 Braun John T Devices and methods for the correction and treatment of spinal deformities
US6966911B2 (en) * 2002-01-22 2005-11-22 Jorge Abel Groiso Bone staple and methods for correcting bone deficiencies by controllably suppressing and/or inducing the growth of the epiphyseal plate
US20050021035A1 (en) * 2002-01-22 2005-01-27 Groiso Jorge Abel Bone staple and methods for correcting bone deficiencies by controllably suppressing and/or inducing the growth of the epiphyseal plate
US7052497B2 (en) * 2002-08-14 2006-05-30 Sdgi Holdings, Inc. Techniques for spinal surgery and attaching constructs to vertebral elements
US20040034351A1 (en) * 2002-08-14 2004-02-19 Sherman Michael C. Techniques for spinal surgery and attaching constructs to vertebral elements
US20040102774A1 (en) * 2002-11-21 2004-05-27 Trieu Hai H. Systems and techniques for intravertebral spinal stabilization with expandable devices
US20050080420A1 (en) * 2003-08-20 2005-04-14 Farris Robert A. Multi-axial orthopedic device and system
US20050171539A1 (en) * 2004-01-30 2005-08-04 Braun John T. Orthopedic distraction implants and techniques
US20050216004A1 (en) * 2004-03-23 2005-09-29 Schwab Frank J Device and method for dynamic spinal fixation for correction of spinal deformities
US20050234451A1 (en) * 2004-04-16 2005-10-20 Markworth Aaron D Pedicle screw assembly
US20050283157A1 (en) * 2004-06-17 2005-12-22 Coates Bradley J Multi-axial bone attachment assembly
US20060235392A1 (en) * 2004-08-27 2006-10-19 Hammer Michael A Multi-axial connection system
US20060155279A1 (en) * 2004-10-28 2006-07-13 Axial Biotech, Inc. Apparatus and method for concave scoliosis expansion
US20060116677A1 (en) * 2004-12-01 2006-06-01 Burd Brian A Side-loading bone anchor

Also Published As

Publication number Publication date
US20030027124A1 (en) 2003-02-06
US6969610B2 (en) 2005-11-29

Similar Documents

Publication Publication Date Title
US20100297219A1 (en) Methods and Compositions for Modifying Apolipoprotein B mRNA Editing
US6969610B2 (en) Methods of modifying cell structure and remodeling tissue
JP2000505300A (en) Recombinant ribonuclease protein
US7018631B1 (en) Compositions and methods for sensitizing and inhibiting growth of human tumor cells
KR100495140B1 (en) Cell-transducing transport domain fusion protein and use thereof
US8455427B2 (en) Methods of modifying insulin signaling using biliverdin reductase
US20100098679A1 (en) Promotion of peroxisomal catalase function in cells
US6090621A (en) Signaling inositol polyphosphate 5-phosphatases (SIPs)
US20050119205A1 (en) Methods of modulating heme oxygenase-1 expression and treating heme oxygenase-1 mediated conditions
US9068174B2 (en) Method for sensitizing tumor cells to chemotherapeutic prodrug CPT-11
US20050287132A1 (en) Biliverdin reductase fragments and variants, and methods of using biliverdin reductase and such fragments and variants
WO2009149307A2 (en) Compositions and methods for restoring mitochondrial electron transfer function
JP2006515168A5 (en)
Lee et al. Human brain pyridoxal-5'-phosphate phosphatase (PLPP): protein transduction of PEP-1-PLPP into PC12 cells
KR20060017348A (en) Cellular Inducible Botoxin Fusion Protein
US9492510B2 (en) Composition and method for inhibiting tumor cell growth
JP6061932B2 (en) Compositions and methods for specifically regulating pyruvate dehydrogenase kinase
US20130344053A1 (en) Methods of Modifying Insulin Signaling Using Biliverdin Reductase (BVR) and BVR Derived Peptides

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF ROCHESTER;REEL/FRAME:038093/0243

Effective date: 20160324